As filed with the Securities and Exchange Commission on June 30, 2006
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2005
OR
o TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
OR
o SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report: N/A
Commission file number: 0-29860
SKYEPHARMA PLC
(Exact name of Registrant as specified in its charter)
England and Wales
(Jurisdiction of incorporation or organization)
105 Piccadilly, London W1J 7NJ, England
(Address of principal executive offices)
Securities registered or to be registered pursuant to Section 12(b) of the Act: None
Securities registered or to be registered pursuant to Section 12(g) of the Act:
Ordinary Shares of 10p each (Ordinary Shares) represented by American Depositary Shares (ADSs) quoted on the NASDAQ National Market System, each ADS representing ten Ordinary Shares.
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by this Annual Report:
Ordinary Shares, nominal value 10p each 753,764,146
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o |
|
Accelerated filer x |
|
Non-accelerated filer o |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes x No o
Indicate by check mark which financial statement item the registrant has elected to follow:
Item 17 x |
Item 18 o |
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes o No x
|
|
|
Page |
|
|
3 |
|||
|
4 |
|||
|
4 |
|||
|
5 |
|||
|
|
|||
|
|
6 |
||
|
|
6 |
||
|
|
6 |
||
|
|
22 |
||
|
|
47 |
||
|
|
48 |
||
|
|
64 |
||
|
|
75 |
||
|
|
78 |
||
|
|
78 |
||
|
|
79 |
||
|
|
90 |
||
|
|
93 |
||
|
|
|||
|
|
94 |
||
|
Material Modifications to the Rights of Security Holders and Use of Proceeds |
|
94 |
|
|
|
94 |
||
|
|
95 |
||
|
|
95 |
||
|
|
95 |
||
|
|
96 |
||
|
Purchase of Equity Securities by the Issuer and Affiliated Purchasers |
|
96 |
|
|
|
|||
|
|
97 |
||
|
|
97 |
2
In this Annual Report on Form 20-F (Form 20-F), the term Ordinary Shares refers to the Ordinary Shares, nominal value 10 pence each, of SkyePharma PLC (SkyePharma or the Company, and together with its consolidated subsidiaries, the Group) and the term ADSs refers to American Depositary Shares each representing the right to receive 10 Ordinary Shares and evidenced by American Depositary Receipts (ADRs).
The Company publishes its consolidated financial statements expressed in pounds sterling. In this Annual Report, references to pounds sterling, £, pence or p are to the lawful currency of the United Kingdom; references to U.S. dollars or $ are to the lawful currency of the United States; references to Euro or e are to the lawful currency of the members of the European Union that have adopted the single European currency; references to $ Canadian or Cdn$ are to the lawful currency of Canada, references to Swiss francs or Chf are to the lawful currency of Switzerland and references to Swedish Krona or SKr are to the lawful currency of Sweden. Solely for the convenience of the reader, this Annual Report contains translations of certain pound sterling amounts into U.S. dollar amounts at specified rates. Unless otherwise stated, the translations of pounds sterling into U.S. dollars have been made at the noon buying rate in New York City for cable transfers in pounds sterling, as certified for customs purposes by the Federal Reserve Bank of New York (the Noon Buying Rate). No representation is made that pounds sterling have been, could have been or could be converted into U.S. dollars at the rates indicated or at any other rate.
Unless otherwise indicated, historical consolidated financial information for the years ended December 31, 2004 and 2005 included herein has been prepared in accordance with International Financial Reporting Standards as adopted by the European Union (IFRS), with a reconciliation of significant differences between IFRS and generally accepted accounting principles in the United States (U.S. GAAP) . The transition date to IFRS for SkyePharma is January 1, 2004. For SkyePharma there are no differences between IFRS as adopted for use in the European Union and full IFRS as published by the International Accounting Standards Board. Prior to 2005, the Company prepared its annual consolidated financial statements under U.K. Generally Accepted Accounting Principles (U.K. GAAP). For the year ended December 31, 2005, the Company has prepared its annual consolidated financial statements in accordance with International Financial Reporting Standards and International Financial Reporting Interpretations Committee (IFRIC) interpretations as adopted by the European Union (EU) applicable to companies reporting under IFRS. The 2004 comparatives have been restated as part of the first-time adoption requirements of IFRS. As allowed by SEC rules in relation to first-time adoption of IFRS, only one year of comparatives is reported in this annual report.
IFRS differ in certain significant respects from U.S. GAAP. For a description of the principal differences between IFRS and U.S. GAAP as they relate to SkyePharma and a reconciliation to U.S. GAAP of the Companys IFRS loss for the years ended December 31, 2005 and 2004 and shareholders funds at December 31, 2005 and 2004, see Note 37 of the Notes to the Consolidated Financial Statements included in Item 17 of this Form 20-F.
Amounts previously reported in this Annual Report for the Companys consolidated shareholders funds in accordance with U.S. GAAP for the fiscal years ended December 31, 2001, 2002, 2003 and 2004 have been restated. This restatement reduced the Companys shareholders funds under U.S. GAAP but did not affect our net loss under U.S. GAAP or financial statements under IFRS. Further information is provided in Item 5: Operating and Financial Review and Prospects, Item 15: Controls and Procedures and Note 37 to the consolidated financial statements beginning on page F-1 of this Annual Report.
3
Except where otherwise indicated, figures included in this Form 20-F relating to pharmaceutical market sales are obtained from the Companys collaborative partners.
This Form 20-F contains certain forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, with respect to the financial condition, results of operations and business of the Company and certain of the plans and objectives of the Board of Directors of the Company with respect thereto. Such statements may generally, but not always, be identified by the use of words such as anticipates, should, expects, estimates, believes or similar expressions. Such statements in this Form 20-F include, but are not limited to, statements under the following headings: (1) Item 4: Information on the Company; (2) Item 5: Operating and Financial Review and Prospects; (3) Item 8: Financial Information; and (4) Item 11: Quantitative and Qualitative Disclosures About Market Risk. Specific risks faced by the Company are described under Item 3: Key InformationRisk Factors. The Companys intention to divest its injectable business interests is described under Item 4: Information on the CompanyBusiness Operations. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. By their nature, forward-looking statements involve risk and uncertainty, and the factors described in the context of such forward-looking statements in this Form 20-F could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements.
STATEMENTS REGARDING COMPETITIVE POSITION
Statements made in Item 4: Information on the Company referring to the Companys competitive position are based on our beliefs, and in some cases rely on other publicly available information.
4
The table below sets forth, for the periods and dates indicated, certain information concerning the Noon Buying Rates for pounds sterling expressed in U.S. dollars per pound. The period average data set forth below is the average of the Noon Buying Rates on the last day of each full month during the period.
Fluctuations in the exchange rate between the pound sterling and the U.S. dollar will affect, among other things, the U.S. dollar equivalent of the pound sterling price of the Companys Ordinary Shares on the London Stock Exchange (LSE), which is likely to affect the market prices of its ADSs in the United States.
|
High |
|
Low |
|
Period Average |
|
Period End |
|
|||||
2001 |
|
1.5045 |
|
1.3730 |
|
|
1.4382 |
|
|
|
1.4543 |
|
|
2002 |
|
1.6095 |
|
1.4074 |
|
|
1.5025 |
|
|
|
1.6095 |
|
|
2003 |
|
1.7842 |
|
1.5500 |
|
|
1.6450 |
|
|
|
1.7842 |
|
|
2004 |
|
1.9482 |
|
1.7544 |
|
|
1.8356 |
|
|
|
1.9160 |
|
|
2005 |
|
1.9310 |
|
1.7114 |
|
|
1.8057 |
|
|
|
1.7188 |
|
|
|
High |
|
Low |
|
|
December 2005 |
|
1.7726 |
|
1.7168 |
|
January 2006 |
|
1.7873 |
|
1.7388 |
|
February 2006 |
|
1.7796 |
|
1.7290 |
|
March 2006 |
|
1.7554 |
|
1.7260 |
|
April 2006 |
|
1.8318 |
|
1.7370 |
|
May 2006 |
|
1.8906 |
|
1.8397 |
|
On June 23, 2006 the Noon Buying Rate was 1.8204 per £1.00 |
|
1.8204 |
|
1.8204 |
|
For a discussion of the impact of exchange rate fluctuations on the Companys operating results, see Item 5: Operating and Financial Review and ProspectsOperating Results.
5
Item 1: Identity of Directors, Senior Management and Advisers
Not applicable
Item 2: Offer Statistics and Expected Timetable
Not applicable
Item 3: Key Information
As part of the European Commissions plan to develop a single European capital market, the application of IFRS is mandatory for the consolidated financial statements of all listed European Union companies for reporting periods beginning on or after January 1, 2005. Under the regulation passed by the European Union, January 1, 2004 is the transition date to IFRS for the Company. Under the IFRS transition provisions within the Securities and Exchange Commissions (SECs) Form 20-F requirements, the Company is permitted to provide two years of comparable financial information under IFRS and reconciliations to U.S. GAAP for the periods presented.
The transition date to IFRS for SkyePharma PLC is January 1, 2004. Therefore, the 2005 and 2004 selected consolidated financial data presented below is in accordance with IFRS and has been derived from our audited consolidated financial statements, including the related Notes, contained elsewhere in this Annual Report. Additionally the selected consolidated financial data presented in accordance with U.S. GAAP below as of and for each of the last five fiscal years ended December 31, 2005 have been derived from our audited consolidated financial statements for the relevant periods.
As noted, we report our financial information in accordance with IFRS. The principal differences between IFRS and U.S. GAAP that are relevant to our consolidated financial statements are discussed in note 37 to our consolidated financial statements beginning on page F-1 of this Annual Report.
The Company has prepared its audited consolidated financial statements assuming that it will continue as a going concern. However, the Companys independent auditors, PricewaterhouseCoopers LLP, has included an emphasis of matter paragraph related to going concern in their auditors report, which refers to Note 1 to the consolidated financial statements beginning on page F-1 to this Annual Report stating that there is uncertainty as to when certain strategic initiatives may be concluded impacting the Groups working capital requirements. The audit opinion has not been qualified in this respect. The Companys audited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. See Report of Independent Registered Public Accounting Firm and note 1 (a) to our consolidated financial statements beginning on page F-1 of this Annual Report.
The selected financial data set forth below for the Company, for the years ended December 31, 2005, 2004, 2003, 2002 and 2001, has been derived from, and should be read in conjunction with, the Companys audited Consolidated Financial Statements, including the Notes to those Statements included in this report.
For exchange rate information, see Exchange Rate Information on page 5 of this Form 20-F. Solely for the convenience of the reader, the pound sterling amounts as of and for the year ended December 31, 2005 have been translated into U.S. dollars at the Noon Buying Rate on December 31, 2005 of $1.7188 per £1.00.
For a discussion of the impact of exchange rate fluctuations on the Companys operating results, see Item 5: Operating and Financial Review and ProspectsOperating Results.
6
The following table sets forth selected consolidated financial information as of and for the five years ended December 31, 2005.
The following table presents selected consolidated financial information of SkyePharma PLC. You should read this table together with Item 5: Operating and Financial Review and Prospects and our audited consolidated financial statements, including the related Notes, contained elsewhere in this annual report.
Consolidated Income Statement Data
|
|
For the year ended December 31, |
|
||||
|
|
2004 |
|
2005 |
|
2005 |
|
|
|
(in millions, except per share data) |
|
||||
IFRS |
|
|
|
|
|
|
|
Revenue |
|
£75.2 |
|
£61.3 |
|
$105.4 |
|
Cost of sales |
|
(28.2 |
) |
(29.2 |
) |
(50.2 |
) |
Gross profit |
|
47.0 |
|
32.1 |
|
55.2 |
|
Selling, marketing and distribution expenses |
|
(1.7 |
) |
(5.9 |
) |
(10.1 |
) |
Administration expenses |
|
(22.5 |
)(1) |
(37.3 |
)(4) |
(64.1 |
)(4) |
Research and development expenses |
|
(28.0 |
) |
(26.0 |
) |
(44.7 |
) |
Other income/(expense) |
|
2.1 |
(2) |
(0.4 |
) |
(0.8 |
) |
Operating loss |
|
(3.1 |
) |
(37.5 |
) |
(64.5 |
) |
Finance costs |
|
(23.9 |
)(3) |
(22.3 |
) |
(38.3 |
) |
Finance income |
|
8.6 |
|
10.0 |
|
17.2 |
|
Share of loss in associate |
|
|
|
(0.8 |
) |
(1.4 |
) |
Loss before income tax |
|
(18.4 |
) |
(50.6 |
) |
(87.0 |
) |
Income tax expense |
|
(0.2 |
) |
(0.3 |
) |
(0.5 |
) |
Loss for the year |
|
(18.6 |
) |
(50.9 |
) |
(87.5 |
) |
Basic and diluted weighted average number of shares in issue |
|
615.2 |
|
624.9 |
|
624.9 |
|
Basic and diluted loss per Ordinary Share |
|
(3.0 |
p) |
(8.1 |
p) |
(14.0 |
c) |
|
|
For the year ended December 31, |
|
||||||||||
|
|
2001 |
|
2002 |
|
2003 |
|
2004 |
|
2005 |
|
2005 |
|
|
|
(in millions, except per share data) |
|
||||||||||
U.S. GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
£44.2 |
|
£42.6 |
|
£66.6 |
|
£75.2 |
|
£56.3 |
|
$96.8 |
|
Operating loss |
|
£(27.5 |
) |
£(36.2 |
) |
£(22.1 |
) |
£(1.3 |
) |
£(33.0 |
) |
$(56.7 |
) |
Net loss under U.S. GAAP |
|
£(44.9 |
) |
£(50.0 |
) |
£(38.6 |
) |
£(20.8 |
) |
£(49.2 |
) |
$(84.6 |
) |
Basic and diluted net loss per share |
|
(8.5 |
p) |
(8.7 |
p) |
(6.3 |
p) |
(3.4 |
p) |
(7.9 |
p) |
(13.5 |
c) |
(1) Administration expenses in 2004 include £1.2 million relating to the reorganization of some research and development operations and other business functions and a charge of £3.5 million for a provision for diminution in value of fixed asset investments.
(2) Other operating income in 2004 includes income of £2.0 million relating to the profit on disposal of the Groups investment in Transition Therapeutics.
(3) Finance costs in 2004 include an exceptional charge of £6.2 million relating to the exchange of convertible bonds.
7
(4) Administration expenses in 2005 include £19.4 million relating to an impairment of the investments in Astralis, Vital Living and Micap since following the Strategic Review and the Groups decision to focus on its core oral and pulmonary products and to divest its injectable business, the Group no longer views its collaborations with Astralis, Vital Living and Micap as strategic, and a £2.0 million charge for legal and professional fees relating to an aborted strategic transaction.
Consolidated Balance Sheet Data
|
|
For the year ended December 31, |
|
||||
|
|
2004 |
|
2005 |
|
2005 |
|
|
|
(in millions, except number of shares) |
|
||||
IFRS |
|
|
|
|
|
|
|
Fixed assets |
|
£155.8 |
|
£134.4 |
|
$231.0 |
|
Cash and short term bank deposits |
|
15.3 |
|
34.3 |
|
59.0 |
|
Total assets |
|
191.9 |
|
186.9 |
|
321.2 |
|
Net Assets(1) |
|
36.5 |
|
31.9 |
|
54.8 |
|
Share Capital |
|
63.4 |
|
76.6 |
|
131.7 |
|
Number of shares |
|
622,398,743 |
|
753,764,146 |
|
753,764,146 |
|
|
|
For the year ended December 31, |
|
||||||||||||||||||||||||
|
|
2001 |
|
2002 |
|
2003 |
|
2004 |
|
2005 |
|
2005 |
|
||||||||||||||
|
|
(in millions) |
|
||||||||||||||||||||||||
U.S. GAAP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total assets(2)(3) |
|
|
£ |
281.4 |
|
|
|
£ |
302.2 |
|
|
|
£ |
271.4 |
|
|
|
£ |
216.2 |
|
|
£ |
222.8 |
|
$ |
382.9 |
|
Net Assets(1)(2)(3) |
|
|
117.9 |
|
|
|
109.8 |
|
|
|
69.6 |
|
|
|
58.9 |
|
|
50.0 |
|
85.9 |
|
||||||
(1) Net Assets is equivalent to shareholders funds.
(2) Under U.S. GAAP total assets and net assets have been restated to properly present changes in the Companys goodwill balances related to acquired subsidiaries which are outside the United Kingdom. In prior years the Company had made no adjustment for the difference in accounting treatment that exists between UK GAAP and U.S. GAAP in respect of the impact of foreign exchange translation upon consolidation of these subsidiaries. This restatement reduced the Companys shareholders funds under U.S. GAAP but did not affect its net loss under U.S. GAAP or financial statements under IFRS. Further information is provided in Item 5: Operating and Financial Review and Prospects, Item 15: Controls and Procedures and Note 37 to the consolidated financial statements beginning on page F-1 of this Annual Report.
(3) Under U.S. GAAP total assets and net assets have been restated due to a change in accounting principle relating to the investment in Astralis. This is caused by a change in classification from an available for sale to an equity method investment due to the ability to exercise significant influence.
For a reconciliation of the Companys IFRS shareholders funds to U.S. GAAP, see Note 37 of the Notes to the Consolidated Financial Statements.
8
The Company is exposed to certain risks that arise from the activity of developing and manufacturing drug products.
Extensive government regulation may cause increased costs and delays in developing and marketing products
The Company is subject to extensive government regulation. The U.S. Food and Drug Administration (FDA), the European Medicines Evaluation Agency (EMEA) and other national regulatory authorities require rigorous pre-clinical testing, clinical trials and other procedures prior to approving drugs for human use. Numerous regulations also govern the manufacturing, safety, labeling, storage, record keeping, reporting and marketing of such drugs. These requirements vary widely from country to country, as does the time required to complete pre-clinical testing and clinical trials and to obtain regulatory approvals to sell drugs. The process of obtaining these approvals and complying with applicable government regulations is time consuming and expensive. If the FDA or other national regulatory authorities increase the number of clinical trials required for the approval of drugs, the Company could face increased costs and significant development delays before the Company will be able to sell its products commercially. In addition, changes in regulatory policy or additional regulations adopted during product development could also result in delays or rejections in obtaining marketing approvals from regulatory authorities.
Most of the products that the Company develops will require a new drug application (NDA) filing with the FDA before they can be marketed in the United States. Based on current practice, the Company generally expects it to take less than two years from the date of filing for the FDA to approve an NDA for a product formulation. However, the Company cannot predict the exact time required or the outcome of the approval process for any of its product candidates with any certainty.
A number of products using the Companys technologies have not yet been approved for marketing by regulators. These product candidates are at various stages of development, ranging from pre-clinical studies to Phase III clinical trials and those that have been filed for approval. The Company cannot be certain that its product candidates will prove safe and effective in clinical trials or that it will obtain further regulatory approvals of any such products. These products will require expensive and lengthy testing and regulatory clearances before they can be sold commercially.
Products for which the Company obtains regulatory approval may not succeed in the market
Although the Company carries out commercial feasibility assessments and extensive clinical trials on all its products before they are launched, newly launched products may not achieve broad market acceptance. The successful launch of a new pharmaceutical product involves a substantial investment in sales and marketing costs, launch stocks and other items. If a new product cannot be manufactured at an acceptable cost or does not succeed as anticipated or its rate of sales growth is slower than anticipated, there is a risk that it could have a material adverse effect on the Companys financial condition and results of operations.
In addition, pre-clinical testing or clinical testing may not accurately predict safety or effectiveness in broader human use. For a new product, it can be difficult to establish from available data a meaningful and reliable assessment of its eventual efficacy and/or safety in the market.
Competition and technological change may render the Companys products or technologies uncompetitive or obsolete
The drug development industry is highly competitive and rapidly evolving, with significant developments expected to continue at a rapid pace. The Companys success will depend on maintaining a
9
competitive position and developing efficient and cost-effective products and technologies. The Companys products will compete with other drugs and methods for delivering drugs. The Company cannot be certain that any of its products will have advantages that will be significant enough to cause medical professionals to prescribe or recommend them. New drugs or further development in alternative drug delivery methods may provide greater benefits or may offer comparable performance at lower cost than the Companys products or technologies. The Company cannot be certain that developments by other companies will not render its products or technologies uncompetitive or obsolete.
Many of the Companys competitors have longer operating histories and greater financial, marketing and other resources. Such competitors may prove to be more successful in developing competing technologies, obtaining regulatory approvals and marketing their products than the Company because of greater financial resources, stronger sales and marketing teams or other factors.
The Company will face competition with respect to the products it is developing under its collaborative arrangements with leading pharmaceutical companies including competition from other products developed and produced by the Companys collaborative partners and branded and generic products manufactured by other companies.
The Companys business may give rise to product liability claims not covered by insurance or indemnification
The design, development and manufacture of the Companys products involve an inherent risk of product liability claims.
Although the Company generally relies on indemnity provisions in its agreements with its collaborative partners to protect itself against the possibility of product liability claims, the Company has obtained product liability insurance in respect of pharmaceutical products it is developing in conjunction with such partners. This product liability insurance also covers liabilities associated with the commercial sale of products marketed by third parties using the Companys technology.
The Company has also obtained clinical trial insurance for current human clinical trials and bio-equivalence studies involving its products under development and intends to obtain insurance for future clinical trials and bio-equivalence studies of additional products under development.
The Company believes that its product liability and clinical trial insurance, together with the indemnity provisions in its collaborative agreements, is adequate for current operations. However, the coverage limits of this insurance and the indemnity provisions in the Companys collaborative agreements may not be adequate to cover all potential claims. Product liability and clinical trial insurance is expensive and may be difficult to obtain or maintain on commercially reasonable terms. A successful claim against the Company in excess of the Companys insurance coverage or outside the scope of the indemnity given by its collaborative partners could adversely affect the Companys results of operations.
The Companys revenues may be reduced and costs increased as a result of third-party payor cost containment measures
The Companys ability to achieve profitability in its businesses depends in part on the extent to which appropriate levels of reimbursement for products and related treatments are obtained from government authorities, private health insurers and other organizations, such as health maintenance organizations. These third-party payors are increasingly challenging the pricing of pharmaceutical products and seeking ways to replace more expensive pharmaceuticals with cheaper alternatives. The trend toward managed healthcare in the United States and the growth of organizations such as health maintenance organizations in the United States could significantly influence the purchase of pharmaceutical products, thereby resulting in lower prices and reduced demand for the Companys products under development. Such cost
10
containment measures could affect the Companys ability to sell products under development and may adversely affect the Company.
Healthcare reform proposals may adversely affect the Companys business
The efforts of governments to contain or reduce the cost of health care will continue to affect the business and financial condition of drug companies. A series of health care reform proposals announced in recent years have created uncertainty that could adversely affect the Companys ability to raise funds and to identify and reach agreements with potential partners. Such proposals could adversely affect the Companys business. Furthermore, the Companys ability to commercialize potential products may be adversely affected to the extent such proposals have an adverse effect on the business, financial condition and profitability of other companies that are the Companys current or prospective collaborators for some of such products.
The Company may not be able to divest its injectable business interests
In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash position, the Company should concentrate on oral and inhalation products, and divest its injectable business interests. A sale of these interests would include the sale of the manufacturing and other facilities in San Diego, California. However, there can be no assurance that the Company will be able to agree on suitable terms of sale with an appropriate purchaser, or that any sale would ultimately be completed. A failure to divest the Companys injectable business interests could prevent the Company from executing its strategy and adversely affect the Companys results of operations.
Moreover, until such time as the Company is able to divest its injectable business interests, it remains subject to certain risks inherent in the licensing and manufacturing of DepoFoam as described elsewhere in these Risk Factors.
The Companys near term working capital requirements are uncertain and sensitive to the timing of a number of initiatives required to provide the financial flexibility to implement its new strategy
The Companys working capital requirements continue to be affected by the timing and receipt of milestone payments and payments received on the signing of new contracts. The Companys future cash flows will also be impacted by the Companys change in strategy, principally its stated aim of moving to sustainable profitability in the near term and its refocus to concentrate on oral and pulmonary products. Consequently the Companys near term working capital requirements are uncertain and sensitive to the timing of a number of initiatives required to provide the financial flexibility to implement the new strategy. These initiatives include the licensing of Flutiform in Europe, the divestment of the Companys injectable business interests, which is expected to require shareholder approval, or the US licensing for DepoBupivacaine.
The Companys independent auditors, PricewaterhouseCoopers LLP, have included an emphasis of matter paragraph related to going concern in their auditors report, which refers to Note 1 to the consolidated financial statements beginning on page F-1 to this Annual Report stating that there is uncertainty as to when certain strategic initiatives may be concluded impacting the Groups working capital requirements. The audit opinion has not been qualified in this respect.
The Board of Directors has reviewed the working capital requirements of the Group for the next twelve months and has a reasonable expectation that sufficient funds will be raised from these initiatives and has therefore prepared the financial information contained herein on the basis that the Company will continue in operational existence for the foreseeable future. The financial statements do not reflect any
11
adjustments that would be required to be made if they were to be prepared on a basis other than a going concern basis.
In the event that sufficient funds are not raised by the Companys initiatives and currently available funds and internally generated cash flow are not sufficient to satisfy its financing needs, the Company will be required to seek additional funding through other arrangements with corporate collaborators, through bank borrowings or through public or private sales of its securities, including equity securities. Any such collaboration could result in limitations on the resources the Company could devote to research, development and commercialization of new products and product candidates, if any, as well as its profits therefrom. In addition, the terms of any future bank borrowings could place restrictions on the Companys ability to take certain actions, and any equity financing could result in dilution to the Companys shareholders. The Company does not currently have any committed sources of additional capital.
For more information on the Companys liquidity and capital resources, see Item 5: Operating and Financial Review and Prospects.
The Companys revenues tend to fluctuate
The Companys revenues principally derive from contract development. Contract development revenues include milestone payments and that portion of the Companys research and development expenses that the Company charges to its partners pursuant to collaborative arrangements with these partners. The amount of the Companys contract development revenue in any given period will depend on a number of unpredictable factors, including scientific developments, the ability of the Company to find suitable partners, the timing of the negotiation and conclusion of agreements with such partners, whether and when the Company achieves milestones agreed with its partners, such as the timing of regulatory approvals and the market introduction of new products, and other factors. As a result, the Companys revenues tend to fluctuate materially on a monthly, semi-annually and yearly basis. The Company believes that its revenues will continue to fluctuate in the near to medium term as a result of the factors described above.
The Company may not achieve and sustain profitability
In 2005, SkyePharma reported a full year net loss of £50.9 million and in 2004 a full year net loss of £18.6 million. As a result of these losses, the Companys consolidated net assets at December 31, 2005 declined to £31.9 million, compared with £36.5 million at December 31, 2004. If and when the Company achieves profitability is dependent upon a number of factors, including the timing and recognition of milestone payments and license fees received, the timing of contract development revenues and the amount of discretionary investment the Company chooses to make in furthering its own product portfolio. As a consequence, the Company cannot assure you that it will be able to achieve and sustain profitability. See Item 5: Operating and Financial Review and Prospects.
In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectable business interests. However, there can be no assurance that the Company will be able to agree on suitable terms of sale with an appropriate purchaser, or that any sale would ultimately be completed.
Other factors that will affect whether the Company achieves and sustains profitability include its ability, alone or together with its partners, to:
· develop products utilizing its technologies, either independently or in collaboration with other pharmaceutical companies;
12
· receive necessary regulatory and marketing approvals;
· establish and expand its manufacturing;
· achieve market acceptance for its products;
· receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities in line with the Companys current forecasts; and
· maintain sufficient funds to finance its activities.
The Company is dependent on its various technologies, as to which further successful development is uncertain
The Companys ability to increase revenues and achieve profitability is largely dependent on certain of its technologies. Approximately 36% of the Companys revenues for the year ended December 31, 2005 derived from royalties, product sales, contract development and milestone payments relating to its Geomatrix technologies, approximately 20% from royalties, product sales, contract development and milestone payments relating to its inhalation technologies and approximately 17% from royalties, product sales, contract development and milestone payments relating to its DepoFoam technologies. In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectable business interests. In order to increase revenues from its technologies, the Company must continue to obtain new development contracts with third parties or develop, license and manufacture new formulations of commercially available drugs using these technologies. The Company cannot assure you that it will be able to obtain such contracts or successfully develop new formulations internally.
There can be no assurance that the Company will be able to develop successfully future products using its various technologies. The development and formulation of oral and injectable controlled release and inhalation products is difficult and time-consuming. Each drug compound is different, and there can be no assurance that a drug delivery system that works with one product will work with another.
Even after a product incorporating the Companys technologies has been successfully formulated and approved, its commercial success is not assured. In order to gain medical and commercial acceptance, a product generally must demonstrate some performance improvements and other benefits over products incorporating the same or similar drug compounds. In some cases, these benefits may be difficult to establish.
Failure by the Companys collaborative partners to fulfil their obligations to the Company to provide funding, obtain regulatory approvals and conduct marketing activities could adversely affect the Companys business
The Companys ability to develop and market its present and future products depends in large part on its ability to maintain its existing, and enter into new collaborations with third parties. If any of the Companys partners becomes insolvent or terminates or otherwise fails to fulfil its obligations with the Company, the Companys business could be adversely affected. In particular, the Company faces the following risks with respect to collaborative partners:
· Funding. The Company has entered into a number of collaborative arrangements with various pharmaceutical companies for the development and commercialization of products using its technologies. Some of the Companys collaborative partners are, however, development stage companies whose business prospects are uncertain and who face similar risks as the Company. If the Company becomes unable to continue to obtain funding for its development activities through its collaborative arrangements or if its collaborative partners fail to make payments due under the
13
development and commercialization agreements, the Companys business would be adversely affected.
· Regulatory Approvals. The Company generally depends upon its collaborative partners to secure the necessary regulatory approvals of new pharmaceutical formulations utilizing its technologies. In these cases, the Company has no control over the timing of the regulatory filings and in which countries they may be filed. Its partners may follow a regulatory strategy that does not maximize the royalty income that the Company may receive from its technologies. In addition, the Companys partners may choose not to file for regulatory approval of a product successfully formulated with its technologies. Even if the Companys partners do file for regulatory approval, they may fail to devote the necessary resources and expertise to secure approval.
· Marketing. At present, the Company is not involved in the direct marketing of new products formulated with its technologies and therefore depends on its collaborative partners for such marketing and sales from which it earns revenues including royalties. The Companys future revenues largely depend on the success of such marketing efforts, which are beyond its control. For example, Paxil CR was approved by the FDA in February 1999 but was not launched by GlaxoSmithKline PLC (GlaxoSmithKline) until April 2002 and in March 2005 GlaxoSmithKline announced that the FDA had halted supplies of Paxil CR due to manufacturing issues. GlaxoSmithKline announced the resupply of Paxil CR on June 27, 2005.
A failure to obtain and maintain patents and other proprietary rights may adversely affect the Companys business
The Companys success, competitive position and the amount of milestone and royalty income it receives each depend, in part, on its ability to obtain and maintain patent and other intellectual property protection, particularly for its drug delivery and formulation technologies. Such patent and other intellectual property protection is also important to the Companys business and its future performance will depend in part on its ability to obtain and maintain such protection. The Companys performance will also be affected by its ability to operate without infringing the intellectual property rights of others.
While the Company intends to obtain patents covering as many of its technologies as possible, the process of obtaining patents is lengthy and expensive. There can be no assurance that patents will be granted in connection with any of the Companys currently pending or future applications or that they will be valid and of sufficient scope and strength to provide the Company with meaningful legal protection or any commercial advantage. In addition, intellectual property protection may be unavailable or limited in some of the countries in which the Company does business. The laws of some foreign countries do not afford the Companys inventions the same degree of legal protection as the laws of the United States. In addition, patent laws may change over time. The Company cannot predict the effect that any such changes would have on its business and its ability to protect its current and future products and technologies. If the Company fails to obtain and maintain sufficient protection for its current and future products and technologies, its ability to successfully commercialize these products and technologies could be adversely affected.
The Company, from time to time, may receive notifications of alleged infringement of patents owned by third parties. The Company may not, in all cases, be able to successfully defend itself in court or resolve such allegations through licensing or settlement. Moreover, whether or not the Company is successful in enforcing its own patents or in defending itself against claims of alleged infringements of patents owned by third parties, doing so is time-consuming and costly and may result in the diversion of management resources.
The Company also relies on trade secrets and other unpatented proprietary information in its product and technology development activities. To the extent that the Company relies on trade secrets and
14
unpatented proprietary information to maintain its competitive position, there can be no assurance that others may not independently develop the same or similar products or technologies. The Company seeks to protect trade secrets and proprietary information, in some cases through clauses in confidentiality agreements with its employees, consultants, advisors and collaborators. Nevertheless, these agreements may not effectively prevent disclosure of the Companys proprietary information and may not provide the Company with an adequate remedy in the event of unauthorized disclosure of such information. If the Companys employees, scientific consultants or collaborators develop inventions or processes independently that may be applicable to the Companys products or technologies under development, disputes may arise about ownership of proprietary rights to those inventions and processes. Such inventions and processes will not necessarily become the Companys property, but may remain the property of those persons or their employers. Protracted and costly litigation could be necessary to enforce and determine the scope of the Companys proprietary rights. Failure to protect patent or other unprotected proprietary information, for any reason, would adversely affect the Companys business.
The Company has entered into a number of collaborative arrangements with leading pharmaceutical companies for the development and commercialization of products. In connection therewith, the Company shares certain of its proprietary knowledge with such collaborative partners. Although the Companys patents and other proprietary rights are intended to protect the Company from infringement by such collaborative partners, there can be no assurance that the Companys patents or other proprietary rights will prevent its collaborative partners from developing similar or functionally equivalent products. In addition, the Companys arrangements with its collaborative partners frequently contain representations, warranties and other assurances given by the Company regarding the scope of its own intellectual property and the non-infringement by the Company of intellectual property owned by third parties. If the Company were found to be in breach of any of these provisions, its partners could sue the Company for damages, which could have a material adverse effect on the Companys business, results of operations and financial condition.
The Company also engages in collaborations, sponsored research agreements and other arrangements with academic researchers and institutions, some of which have received and may receive funding from government agencies. Although the Company seeks to retain ownership of all intellectual property rights pertaining to inventions which may result from such collaborations, there can be no assurance that the governments, institutions, researchers or other third parties will not also have certain rights to such inventions.
For more information on the Companys patents and proprietary rights, see Item 4: Information on the CompanyPatents and Proprietary Rights.
15
Failure to comply, or the costs of complying, with environmental, health and safety regulations could adversely affect the Companys business
The Companys business is subject to regulation relating to the protection of the environment and health and safety, including regulations governing air emission, effluent discharge, and the use, generation, manufacture, storage, handling and disposal of certain materials. The Company believes that it is in compliance in all material respects with all such laws, rules, regulations and policies applicable to the Company. However, there can be no assurance that the Company will not be required to incur significant costs to comply with such environmental and health and safety laws and regulations in the future.
A failure to manage expansion effectively could adversely affect the Companys business
Management of the Companys growth, as well as the commencement of commercial manufacturing and marketing of the Companys product candidates, will require continued expansion and improvement of the Companys systems and internal controls and an increase in the Companys manufacturing, marketing and sales operations. Any failure to manage growth effectively and on a timely basis could adversely affect the Companys business.
Failure by the Company to fulfil its obligations to its collaborative partners in respect of manufacturing or to enter into new or maintain its existing manufacturing arrangements could adversely affect the Companys business
The Company has its own manufacturing sites in Lyon, France, Muttenz, Switzerland and San Diego, California. However, for the manufacture of certain of its existing products, and certain of those currently in development, including the Foradil® Certihaler and Flutiform, the Company will depend on manufacturing partners who in some cases are the sole supplier of the services to the Company. If the Company loses one of its current manufacturing partners, fails to enter into agreements with new manufacturing partners, experiences delays in finding such partners or if existing manufacturing partners are unable to supply for any reason, the Companys ability to develop and manufacture products and to meet its obligations in its existing collaborative arrangements could be adversely affected.
Failure by the Company to keep its manufacturing facilities in compliance with required standards could result in delays in manufacturing and additional costs
The Company believes that each of its manufacturing facilities is substantially in compliance with current good manufacturing practices (cGMP) and the applicable regulatory standards. There can be no assurance, however, that the Companys facilities will be found to meet or, in those instances in which a facility has previously been approved for the manufacture of a particular drug, maintain cGMP or applicable regulatory standards. Failure of the Companys manufacturing facilities to meet or maintain such standards could delay or interfere with the Companys plans to scale-up manufacturing or manufacture commercial quantities of its product candidates.
In those instances in which a manufacturing facility has previously been approved, the Companys facilities will need to pass periodic follow-on inspections. The Company may be required to incur significant additional expenses in order to ensure that its facilities remain compliant with cGMP and the applicable regulatory standards.
Flutiform may not successfully complete the development process, achieve regulatory approval or succeed in the market if approved
Due to the inherent risk in the development of pharmaceuticals, it is possible that Flutiform may not successfully complete development and be launched. There can be no assurance that Flutiform will successfully complete clinical studies or that it will meet the regulatory requirements for commercial distribution. Flutiform will be the first product using the Companys metered dose aerosol inhaler (MDI) technology to attempt to access the U.S. market where regulatory barriers to entry are particularly steep. Even if Flutiform is approved for marketing, there can be no assurance that the Company will not experience delays in the development or approval process that could adversely affect the
16
commercial value of Flutiform. Similarly, there can be no assurance that any regulatory approvals will not be more limited in scope than the Company currently expects. The Company currently does not have its own sales and marketing capability and is currently therefore reliant on one or more marketing partners to market Flutiform.
In May 2006, the Company announced that it had entered into an agreement with Kos Pharmaceuticals to jointly develop Flutiform. Kos will have exclusive rights to market Flutiform in the United States and a right of first negotiation in Canada. SkyePharma remains in negotiations with potential partners for Europe and other markets around the world. If, however, the Company does not obtain one or more suitable partners for other territories, the successful marketing of Flutiform may be adversely affected. In addition, while the Company believes there is little prospect of additional competition in the combination market until 2012 at the earliest, Flutiform may not achieve the competitive position that the Company anticipates.
The Company may not be able to maintain its exclusive technology rights to DepoFoam from the Research Development Foundation
The Companys DepoFoam business depends in part on its ability to continue to use technology rights that the Research Development Foundation (RDF) assigned to a subsidiary of the Company on an exclusive basis. Under the agreement, RDF has the right to terminate the agreement or to convert the exclusive nature of the rights granted under the agreement into a non-exclusive right if the subsidiary does not satisfy its contractual obligations, including its obligation to make certain minimum annual payments. RDF may also terminate the agreement if the Companys subsidiary becomes bankrupt, breaches the agreement or contests the patents relating to this technology. The termination of the subsidiarys agreement with RDF or its conversion to a non-exclusive agreement would adversely affect the Companys DepoFoam business.
Failure by the Company to ensure adequate DepoFoam manufacturing capacity could adversely affect the Companys business
If the Company fails to maintain adequate manufacturing capacity in respect of its DepoFoam manufacturing operations, it may be unable to supply DepoCyt® to its marketing partners, Enzon Pharmaceuticals, Inc. (Enzon) for North America and Mundipharma International Holdings Limited (Mundipharma) for the European Union and certain other countries in Europe. Similarly the Company may be unable to supply DepoDur to its North American marketing partner, Endo Pharmaceuticals Inc. (Endo). DepoCyt® is currently marketed in the United States and Europe and DepoDur was launched in the United States in December 2004. The Company will need to expand its current manufacturing operations significantly in order to manufacture additional DepoFoam products. The Company will also need to comply with regulations in the United States and foreign countries relating to achieving the prescribed quality and required levels of production of its DepoFoam products and obtaining marketing approval.
The Company may not be able to obtain the materials necessary to continue to manufacture its DepoFoam products
The Company currently relies on a limited number of suppliers for materials required to manufacture its DepoFoam products. If the Company cannot obtain the materials it needs from its existing suppliers, the Company may not be able to access alternative sources of supply within a reasonable period of time or at commercially reasonable rates. In addition, regulatory requirements applicable to drugs tend to make the substitution of suppliers costly and time-consuming. The unavailability of adequate commercial quantities, the inability to develop alternative sources, a reduction or interruption in supply or a significant increase in the price of materials could adversely affect the Companys ability to manufacture and market its DepoFoam products.
17
The Companys manufacturing process may not be suitable for all of the DepoFoam products the Company desires to commercialize
To date, SkyePharma Inc. has relied on a particular proprietary method of manufacturing its potential DepoFoam products. The Company cannot be certain that this method will be equally suitable to all DepoFoam products it desires to commercialize. The problems that may arise include:
· the Company may not be able to meet manufacturing challenges that arise concerning particular drugs to be incorporated in DepoFoam;
· the Companys manufacturing process may not result in viable yields of DepoFoam products; and
· the physical and chemical stability of DepoFoam products may vary.
If the Company decides to pursue alternative manufacturing methods for some or all of its drugs, it cannot be certain that these methods will prove to be commercially practical or that it will have the right to use any alternative methods.
The Company may not be able to obtain the rights to the drugs it desires to deliver through its DepoFoam technologies
The Companys ability to develop and commercialize its DepoFoam technologies will depend on whether it and its partners can obtain the rights to the drugs, including small molecule chemical compounds and macromolecule biologics, that it intends to deliver through DepoFoam technology. At times, the Company intends to rely on its partners ability to provide this access. The Company cannot be certain, however, that its partners will have appropriate drug candidates for its DepoFoam technology. In addition, the Company or its partners may be alleged or determined to be infringing on third parties rights and may be prohibited from using such drugs or be found liable for damages. Any restriction on access or liability for damages would adversely affect the Companys growth prospects, financial condition and results of operations.
The Company may expend significant time and resources relating to existing and potential legal proceedings and the eventual outcome of such proceedings may differ materially from managements current estimates and beliefs
The Company is currently involved in various legal proceedings, including actions claiming alleged violations of antitrust laws and infringement of intellectual property rights. Although the Company cannot predict the outcome of these proceedings with certainty, the Company believes that these actions are without merit and is vigorously contesting these claims. Contesting these claims, however, may involve the expenditure of significant management time and resources of the Company. In addition, we cannot exclude the possibility that, contrary to managements current estimates and beliefs, the eventual outcome of such matters will have a material adverse effect on the Companys financial position, results of operations or liquidity. For further information on pending litigation, see Item 8: Financial InformationLegal Proceedings.
The Company may incur substantial costs related to its use of hazardous materials
The Companys research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. Although the Company believes that its safety procedures for the handling and disposal of such materials comply with the standards prescribed by the applicable regulations, the Company cannot completely eliminate the risk of accidental contamination or injury from these materials. If such an accident occurs, the Company could be held liable for any damages that result and such liability could exceed the Companys resources and have a material adverse effect on its business, financial condition and results of operations.
18
If the Company is unable to retain key personnel or attract new personnel, it could have an adverse effect on the Companys business
The Company relies upon a number of key executives and employees and its ability to retain and attract other qualified management, scientific, technical, marketing and support personnel. Competition for such personnel is intense, and there can be no assurance that the Company will be able to continue to attract and retain such personnel. The loss of the services of any of the Companys key executives or employees could materially adversely affect its business. Associated with the Companys divestment of its injectable business interests the Company has established a retention plan for its employees within the injectables business.
The Companys efforts to comply with new regulatory requirements, including Section 404 of the Sarbanes-Oxley Act of 2002, could lead to the identification of deficiencies in its system of internal controls, and an inability to remedy such deficiencies could affect the Companys perception by investors
As part of the Companys efforts to comply with Section 404 of the Sarbanes-Oxley Act of 2002 for the year ended December 31, 2006, the Company has committed substantial time and resources to evaluating and assessing the effectiveness of the Companys internal controls over financial reporting. The Companys evaluation and testing is ongoing, and the Company may identify deficiencies in its system of internal controls over financial reporting that require remediation. For example, the Company has identified an error made in respect of goodwill in its reconciliations to U.S. GAAP, where the Company inadvertently recorded the goodwill balances without considering the impact of foreign exchange translation upon consolidation of newly-acquired subsidiaries. As a result, the Company has restated its net assets and shareholders funds under U.S. GAAP to reflect the impact of the adjustments made to the Companys goodwill for the years ended December 31, 2001, 2002, 2003 and 2004. If the Company is not able to remediate this or other identified deficiencies that either alone or together constitute material weaknesses in our internal controls, senior management will not be able to determine that internal controls over financial reporting are effective and comply with Section 404 in a timely manner. This could result in a negative perception of the reliability of the Companys financial statements and a subsequent decline in the price of the Companys Ordinary Shares and ADSs.
Potential conflicts of interests may arise from related party transactions
The Company and certain of its principal shareholders or their affiliates and other formerly related parties have engaged in several significant transactions among themselves in the past. Certain of these historic transactions provide for significant payments to certain principal shareholders, former directors and executive officers upon achievement of specified milestones or profit hurdles. As a result of these arrangements, conflicts of interest may arise between and among the Company, certain principal shareholders, former directors and executive officers. While there is currently no intention to enter into future related party transactions, the Company may do so in the future.
The Company acquired Krypton Limited (Krypton) in a share-for-share exchange in January 1996 from a number of trusts in which Ian Gowrie-Smith, who was then Executive Chairman of the Company, certain former directors and a former employee of the Company had interests. See Item 7: Major Shareholders and Related Party TransactionsCertain Arrangements in Respect of the Krypton Acquisition.
At June 23, 2006, the Company owned 39.8% of Astralis LTD (Astralis). Astralis and the Company are parties to several agreements concerning the development of Astralis novel injectable vaccine therapy, for the treatment of all forms of psoriasis, a chronic skin disorder. See Item 7: Major Shareholders and Related Party TransactionsOther Arrangements.
At June 23, 2006, the Company owned 23.6% of Vital Living, Inc. (Vital Living). The Company has entered into a contract to develop certain products for Vital Living that incorporate its Geomatrix technology. See Item 7: Major Shareholders and Related Party TransactionsOther Arrangements.
19
At June 23, 2006, the Company owned 9.4% of Micap PLC (Micap). During 2003 the Company investigated the pharmaceutical applications of Micaps micro-encapsulation technology in the areas of oral and topical drug delivery. The Company has exercised an option granted to it under one of its agreements with Micap to complete a technology access and license agreement with Micap and has selected ten nominated compounds pursuant to such license. However, it became clear that for those drugs currently under development there were limited applications and so in September 2005, the Company surrendered all rights under the license agreement back to Micap. See Item 7: Major Shareholders and Related Party TransactionsOther Arrangements.
Although the Company anticipates that any future related party transactions and agreements will be on terms no less favorable to the Company than it could obtain in comparable contracts with unaffiliated third parties, there can be no assurance that conflicts of interest will not arise between the Company and the principal shareholders or their affiliates with whom they have entered into agreements.
Exchange rate fluctuations may adversely affect the Companys results of operations and financial position
Approximately 61% of the Companys revenues for the year ended December 31, 2005, were derived from customers located outside the United Kingdom. Since the revenue and expenses of the Companys foreign operations are generally denominated in U.S. dollars, Euros and Swiss francs, exchange rate fluctuations between such currencies and the pound sterling will subject the Company to foreign exchange risk with respect to the reported results of its foreign operations. The Company does not currently hedge against the effect of currency translation on its reported results, but does, where appropriate, seek to hedge its exchange rate risk on particular transactions. Fluctuations between local currencies and the pound sterling may materially adversely affect the Companys financial condition and results of operations. See Item 5: Operating and Financial Review and Prospects.
The Companys Ordinary Shares trade on the London Stock Exchange in pound sterling and the ADSs trade on The Nasdaq National Market in U.S. dollars. The value of the ADSs in U.S. dollars may fluctuate as a result of fluctuations in the U.S. dollar/pound sterling exchange rate.
The market price of the Companys Ordinary Shares and ADSs may be adversely affected by market volatility and liquidity
Companies like SkyePharma have, in recent years, experienced dramatic stock price volatility. The following factors may cause the market price of the Companys Ordinary Shares or ADSs to fluctuate significantly:
· announcements of technological innovations or new products by competitors and others;
· the status of submissions to the FDA or other regulatory authorities;
· variations in results of operations, market condition, analysts estimates and the stock market generally; and
· stock
market perceptions of the pharmaceutical, biotechnology and/ or drug delivery
industries.
The value of shares can go down as well as up and the market in the Companys Ordinary Shares and ADSs may have limited liquidity. The market price of an investment in the Company may not reflect the underlying value of the Companys net assets.
Issuances or sales of a substantial number of the Companys Ordinary Shares or ADSs could adversely affect their market price
Issuances or sales of a substantial number of Ordinary Shares or ADSs could adversely affect the market price of the Companys Ordinary Shares and ADSs. As of June 23, 2006, certain principal shareholders and the directors and officers of the Company, as a group, held 29.6% of the Companys outstanding Ordinary Shares. Shares may be eligible for future sale subject to the conditions imposed by
20
Rule 144 and Regulation S under the Securities Act of 1933. If one or more of the Companys principal shareholders were to sell a substantial portion of the Companys Ordinary Shares or ADSs, the trading price of the Companys Ordinary Shares or ADSs could be adversely affected.
Principal shareholders may influence the outcome of shareholder approvals and hinder a change in control that might be in other shareholders interests
As of June 23, 2006, certain principal shareholders and the directors and officers of the Company as a group owned approximately 29.6% of the Companys outstanding Ordinary Shares. As a result, the directors and officers of the Company, together with such shareholders, may be in a position to influence the election of the Companys directors and officers and other corporate actions that require shareholder approval. This concentration of voting powers may hinder changes or corporate actions that are in the interests of other shareholders.
The Companys shareholders may not receive a return on their shares other than through the sale of their shares
Under current U.K. law, a companys accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be paid. The Company has not paid dividends in the past on its Ordinary Shares. The Company intends to retain earnings, if any, for use in its business and does not anticipate paying any cash dividends in the foreseeable future. Accordingly, other than through the sale of their shares, the Companys shareholders are unlikely to receive a return in the foreseeable future.
21
Item 4: Information on the Company
SkyePharma PLC is a public limited company organized under the laws of England and Wales with its registered office at 105 Piccadilly, London W1J 7NJ, telephone number + 44 (0) 20 7491 1777.
SkyePharma PLC, which was formerly named Black & Edgington Group PLC, was incorporated on 18 February 1910. As Black & Edgington Group PLC, it was engaged in the provision of temporary structures for major events. In January 1996, the name of the Company was changed to SkyePharma PLC and the nature of its activities to pharmaceuticals. Today the Company is a speciality pharmaceutical company, using its multiple drug delivery technologies to create a product pipeline for out-licensing to marketing partners.
The Company, as currently operated, was formed substantially from the 1996 acquisition of Jago Holding AG, the 1999 acquisition of DepoTech Corporation, the 2001 acquisition of RTP Pharma Inc and the acquisition of certain other technologies as set out below.
The Company acquired Jago, a Swiss drug delivery company which commenced operations in 1983, from Dr. Gonella in May 1996. The total consideration paid by the Company to acquire Jago was approximately £100.8 million in cash (plus a prepayment of £3.9 million ($6.0 million)) and approximately 30.7 million Ordinary Shares (valued at 75 pence per share). The Company agreed to pay additional consideration to Dr. Gonella pursuant to an earn-out arrangement. On March 31, 2000, a settlement agreement was signed establishing the full and final settlement of the deferred consideration payable to Dr. Gonella the last remaining provisions of which lapsed on 3, May 2006. See Item 7: Major Shareholders and Related Party TransactionsCertain Arrangements in Respect of the Jago Acquisition. Through the acquisition of Jago, SkyePharma acquired the Geomatrix range of oral controlled release systems and a new generation of inhalation technologies.
In October 1998, the Company acquired 16% of the common stock of DepoTech Corporation (Depotech) of San Diego. In March 1999, the Company acquired the remaining 84% of the outstanding shares by issuing to the former DepoTech shareholders 28.3 million SkyePharma Ordinary Shares in the form of ADSs, plus the right to receive additional shares if certain conditions were satisfied. The conditions were satisfied in 1999 and 2000. Through this acquisition, the Company acquired the DepoFoam technology. DepoTech was renamed SkyePharma Inc. SkyePharma Inc. is SkyePharmas center for the development and manufacture of injectable, sustained-release therapeutic products.
In July 2001, the Company acquired an initial 40.2% of the voting shares of RTP Pharma Inc. (RTP) of Montreal, Canada in return for the issue of SkyePharma Ordinary Shares and acquired $5.0 million (£3.5 million) of preferred shares in RTP for cash. During the following 90 days the Company acquired an additional $10 million (£6.9 million) of preferred shares in RTP in return for the issue of additional SkyePharma Ordinary Shares. In March 2002, the Company announced the completion of the acquisition of the outstanding voting shares in RTP in return for the issue of SkyePharma Ordinary Shares plus deferred consideration which was settled in June 2003. RTP was renamed SkyePharma Canada Inc. (SkyePharma Canada) and specialized in improving the solubility of drugs using its Insoluble Drug Delivery (IDD) technology platform. During 2003, the Company substantially reduced the staff of SkyePharma Canada and outsourced its activities to other SkyePharma sites.
In January 1996, the Company acquired 100% of the outstanding share capital of Krypton, a Gibraltar-based company which holds development rights to certain generic drugs, in return for the issue of Ordinary Shares and warrants to subscribe for additional Ordinary Shares. The Company agreed to pay additional consideration in respect of the Krypton acquisition. See Item 7: Major Shareholders and Related Party TransactionsCertain Arrangements in Respect of the Krypton Acquisition.
22
In January 1997, the Company acquired a pharmaceutical manufacturing and production facility near Lyon, France by acquiring 100% of the issued and outstanding share capital of Laboratories Novalis Production SAS (Novalis), a French company, from Wyeth-Ayerst International Inc., (Wyeth). After the acquisition, Novalis changed its name to Jago Production SAS and later to SkyePharma Production SAS.
In January 2004, SkyePharma converted its 2 million series A convertible preferred shares that it had previously held in Astralis Limited (Astralis), an emerging biotechnology company based and incorporated in the United States, into 25 million common shares, 12.5 million of these being in escrow. In December 2004, SkyePharma signed conditional stock purchase and assignment agreements with two former Astralis directors to acquire 11.2 million common shares of Astralis and appoint a further two directors representing SkyePharma to the Astralis Board. As a result of these events, the investment has been treated as an associated undertaking from December 2004. In March 2005, the conditions of the stock purchase and assignment agreements were satisfied and the Company completed the purchase of 11.2 million shares from the two former directors of Astralis in exchange for approximately 5.5 million common shares in the Company. As at December 31, 2005, the total SkyePharma holding was 36,393,900 common shares and 20,000 warrants, representing approximately 40% of the common shares of Astralis.
In July 1999, the Company acquired intellectual property, license agreements, know-how and trademarks related to nano-particulate drug delivery technology for the delivery of poorly soluble drugs from Medac GmbH (Medac), a private German pharmaceutical company. As consideration for the acquisition, the Company paid cash and issued Ordinary Shares to Medac. In addition, future royalties will be paid to Medac on net sales of marketed products using nano-particulate technology.
In October 1999, the Company acquired the tangible assets and intellectual property of Hyal Pharmaceutical Corporation in Canada (Hyal) from the court-appointed receiver and administrator of Hyal. Hyal was a drug delivery company that developed products using its topical drug delivery technologies based on hyaluronan (also called hyaluronic acid or hyaluronate, HA), a natural polymer, which are primarily designed to maintain efficacy and localize delivery of drugs to the skin for the treatment of a variety of skin disorders.
In December 2000, SkyePharma licensed rights to three topical drug delivery technologies, Crystalip, DermaStick and the ES-Gel system, from Bioglan AB, a Swedish subsidiary of Bioglan Pharma PLC (Bioglan). Under the terms of the agreement, SkyePharma paid cash and obtained certain exclusive development and commercial rights in relation to new products from the Crystalip and DermaStick technologies and also the right to develop with Bioglan two new products using the ES-Gel system.
In May 2002, SkyePharma acquired the entire drug delivery business of Bioglan AB for cash, including acquisition costs, and the assumption of £0.4 million of net liabilities. The acquired rights included Bioglans Biosphere injectable technology and those rights to DermaStick, Crystalip and ES-Gel topical drug delivery technologies that had remained with Bioglan after the December 2000 licensing agreement with Bioglan. During 2004 the Company completed the transfer of the activities of SkyePharma AB to other SkyePharma sites.
In January 2003, SkyePharma announced a strategic investment in Micap PLC (Micap), a private company providing patented micro-encapsulation technology. Micro-encapsulation technology is a process by which tiny droplets or particles of liquid or solid material are surrounded or coated with a continuous film of polymeric material. During 2003, SkyePharma investigated the pharmaceutical applications of Micaps micro-encapsulation technology in the areas of oral and topical drug delivery. In March 2004, the Company exercised an option to enter into a technology access and license agreement with Micap that allows the Company to use Micaps encapsulation technology in up to ten nominated pharmaceutical products to be selected by SkyePharma. However, it became clear that for those drugs currently under development there were limited applications and so in September 2005, the Company surrendered all rights under the license agreement back to Micap.
23
In June 2004, SkyePharma announced that it had entered into a strategic alliance with Vectura Limited (Vectura) in the area of pulmonary delivery technologies. Through this alliance, SkyePharma acquired rights to use Vecturas Aspirair dry powder inhaler device for certain macromolecules on a non-exclusive basis. As part of the alliance, SkyePharma also made an equity investment in Vectura, subscribing for 800,000 ordinary shares at a price of £2.50 per share. In June 2004, Vectura undertook an initial public offering and the Companys shareholding was converted into 3.2 million ordinary shares, representing approximately 3% of Vecturas ordinary share capital. In October 2005, SkyePharma sold 2.0 million of its shares in Vectura. The remaining 1.2 million shares were sold in January 2006. Due to the Companys focus on other inhalation projects, the Company did not progress the alliance on Aspirair and the agreement has now lapsed.
Flutiform
The Company believes that its inhalation product Flutiform has substantial commercial value. However, during 2005 the Company did not complete a development agreement for Flutiform. Faced with the prospect of a delay to the development of this important product, which might have impaired its commercial potential, the Company took the decision in September to raise £35 million (net of expenses) by means of a rights issue to keep Flutiform on its planned development timeline through Phase III. As such, the target launch date for Flutiform in the United States remains 2009.
Prior to reaching the decision to ask shareholders for funding, the Company explored a number of financing alternatives to fund the development of Flutiform and also a variety of strategic options for the Company. These included discussions concerning a transaction that, had it been successful, would have created a combined company that could have marketed Flutiform itself in some markets. The discussions were called off by the Company due to uncertainties over the other partys prospects.
In May 2006 the Company announced that it had entered into an agreement with Kos Pharmaceuticals, to jointly develop Flutiform. Kos will have exclusive rights to market Flutiform in the United States and a right of first negotiation in Canada. SkyePharma remains in negotiations with potential partners for Europe and other markets around the world.
Strategic Review
In November 2005, the Company received a takeover approach from Innovata PLC. As a result, the Board of Directors felt that it was in shareholders interests to explore all options and consequently undertook a full strategic review of all the options open to the Company.
The conclusion of this review in early 2006 did not lead to an offer for the entire Company on terms that the Board of Directors felt able to recommend to shareholders. However, there were expressions of interest in individual parts of the business. The Board announced the outcome of the strategic review on February 2, 2006. The Board concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products and divest its injectable business interests.
Changes in Board of Directors
In January 2006, certain shareholders requisitioned an Extraordinary General Meeting (EGM) seeking to remove the Companys then Chairman and to appoint a nominated director to the Companys Board of Directors with the ultimate aim of having him appointed as Executive Chairman. Although this motion was defeated at the EGM in early March 2006, the Board of Directors has since made a number of changes and introduced a process whereby major investors are now involved in the selection of new Non-Executive Directors. Jerry Karabelas was appointed as Non-Executive Chairman in February 2006, Frank Condella was appointed as Chief Executive Officer in March 2006 and Ken Cunningham was appointed as Chief Operating Officer in April 2006. The changes to the membership of the Companys Board of Directors are set out in Item 6: Directors, Senior Management and EmployeesDirectors and Senior Management.
24
The Company is a specialty pharmaceutical company, using its multiple drug delivery technologies to create a product pipeline for out-licensing to marketing partners. The Company develops novel therapeutic drugs based on its technology platforms for delivering drugs to the human body.
The following table shows the Companys turnover, operating loss and net loss for the two years ending December 31, 2005.
|
|
Year ended |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Revenue |
|
|
|
|
|
Oral, Inhalation and Other |
|
49.6 |
|
50.8 |
|
Injectable |
|
25.6 |
|
10.5 |
|
|
|
75.2 |
|
61.3 |
|
Operating loss pre impairments and abortive transaction costs items |
|
|
|
|
|
Oral, Inhalation and Other |
|
1.0 |
|
2.5 |
|
Injectable |
|
(1.4 |
) |
(18.6 |
) |
|
|
(0.4 |
) |
(16.1 |
) |
Loss for the Year |
|
(18.6 |
) |
(50.9 |
) |
The Companys strategy is to become a leading specialty pharmaceutical company powered through excellence in drug delivery. It uses multiple technologies to build a product pipeline for commercialization through out-licensing to co-development and marketing partners. The Company continually strives to acquire and develop new technologies and products to grow its position in the oral and inhalation drug delivery areas. The Company ultimately plans to selectively market its own products in targeted therapeutic areas.
In late 2005 and early 2006, the Board of Directors conducted a full strategic review of all the options open to the Company and announced the outcome on 2 February 2006. The Board concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectable business interests.
The Companys strategy for achieving these objectives consists of the following elements:
· Divest the injectables business and focus on oral and inhalation products. The proposed divestment of the injectable business interests, which the Company expects to be subject to approval by shareholders, would not only provide cash but also relieve the Company of a significant cash requirement and future capital expenditure. The Company believes that the remaining oral and inhalation business may be able to achieve profitability in the near term. Furthermore, with a more focused use of resources the Company would be in a better position to further develop its pipeline of oral and inhalation products. Funds raised by the divestment of the injectables business will be available to accelerate the development of certain pipeline products whose development has had to be delayed in recent years. Several of these products are at an early stage of development but would address important therapeutic areas. Following the divestment of the injectables business, development activities will continue to be based in Muttenz, Switzerland and manufacturing in Muttenz and Lyon, France.
25
· Selectively Fund a Number of Key Projects to a Later Stage of Development. The Companys strategy in recent years has been to self-fund certain products to a late stage of development, prior to licensing the products to marketing partners. This has allowed the Company to increase its share of the potential revenue streams from these products and gain greater control over the development process. A recent example of this is the Boards decision in September 2005 to fund Phase III clinical trials of Flutiform with the proceeds of a rights issue prior to entering into an out-licensing arrangement with Kos for the North American marketing and distribution rights of Flutiform in May 2006.
· Develop Existing and New Collaborative Agreements. In order to increase the market exposure of its products and to capitalise on its collaborative partners market position and distribution capabilities, the Company intends to continue to develop its projects with its existing collaborative partners, expand its collaborations with existing partners to include new projects, and to seek new partners. In addition, the Company will focus its efforts on working with partners to maximise revenues from existing and future marketed products. The Company has increasingly focused on undertaking additional value added services, such as assuming responsibility for development and regulatory activities and seeking to retain manufacturing and co-marketing rights, which may allow it to increase its share of the potential revenue stream from these collaborations. As part of this strategy, the Company has also reduced its focus on up-front and milestone payments and aimed instead to gain an increased share of royalties and longer term revenues.
· Seek to Retain Manufacturing Rights/and or Marketing Rights on Future Collaborations. The Company employs personnel who specialize in manufacturing products utilizing the Companys technologies in commercial quantities. Where it makes commercial sense, it will pursue long-term manufacturing and supply agreements with licensees of the Companys products. The Company may also seek to retain marketing rights in respect of future products which it could co-market or ultimately market itself in specific targeted therapeutic areas. Currently the Company has no direct marketing capability but at the appropriate time may seek to develop or acquire its own marketing capability. This strategy should not only give it greater control over revenue generation but could also improve gross profit margins.
· Expand the Application of the Companys Core Technologies. The Company intends to continue to expand the application, increase the value and extend the commercial life of its oral, inhalation and enhanced solubilization technologies, by seeking to develop technology improvements, expand patent coverage, acquire complementary technologies and realise synergies between these technologies. The Company may seek to acquire additional add-on technologies, that are complementary to its existing technologies. The Company intends to focus on technologies it believes are capable of commercial realisation in the near term and will also seek to acquire or license new drug delivery platforms and enabling technologies that the Company believes have significant commercial applicability.
The Companys business is comprised of two reportable segments within the meaning of SFAS 131, Oral, Inhalation and Other and Injectable.
Oral, Inhalation and Other
Oral
The original Geomatrix technology was developed by a team of researchers at the University of Pavia in Italy in the early 1980s. The Company acquired the technology through its acquisition of Jago in 1996 and has subsequently pursued the development of the Geomatrix platform of oral controlled-release systems. Geomatrix is a range of technologies by which drugs taken orally in tablet form are
26
formulated so as to control the amount, timing and location of the release of the drug in the body. There are currently eight Geomatrix technologies designed to meet a wide range of therapeutic objectives through different release mechanisms. The technologies are flexible and can be modified to apply to a variety of pharmaceutical products.
The Company collaborates with large pharmaceutical companies to develop Geomatrix formulations of its collaborative partners proprietary products. The Company focuses its research and development efforts on the reformulation of existing drugs using its technologies rather than the discovery of new chemical compounds. In reformulating an existing drug, the Company seeks to enhance the therapeutic and commercial value of the product by creating an improved outcome formulation that may mitigate certain side effects, reduce dosing and extended patent protection.
Approved Geomatrix Products
The following table summarizes certain information on the Companys approved products that utilize Geomatrix technologies. The major marketed products are discussed further below.
Product |
|
|
|
Indication |
|
Regulatory Approvals and |
|
Collaborative Partner |
Paxil CR |
|
CNS |
|
United States (1999) |
|
GlaxoSmithKline |
||
Xatral® OD/Uroxatral® |
|
Genito-Urinary |
|
United States (2003) Europe (2000) |
|
Sanofi-Aventis |
||
Coruno |
|
Angina |
|
Belgium (2002) |
|
Therabel |
||
Madopar DR |
|
Parkinsons Disease |
|
Luxembourg (2003) |
|
Hoffmann-La Roche |
||
Diclofenac-ratiopharm-uno |
|
Arthritis |
|
Germany (1995) |
|
ratiopharm |
Paxil CR is marketed in the United States, Canada and certain other countries. It is a modified release version of Paxil®/Seroxat (paroxetine HCL) which uses a combination of two Geomatrix release systems. Paxil® is an FDA-approved drug that is currently marketed primarily in the United States and Europe and is an immediate release formulation prescribed for central nervous system disorders.
An application for approval of Paxil CR was filed with the FDA by SmithKline Beecham (now part of GlaxoSmithKline) in December 1997 and approved by the FDA in February 1999 for the 12.5 and 25mg dosage forms. In early 2001, GlaxoSmithKline, the Companys collaborative partner in the development of Paxil CR, announced that it had received an approvable letter from the FDA for a second CR indication, panic disorder. On April 19, 2002, Paxil CR was launched in the United States for the treatment of central nervous system and panic disorders. The FDA has subsequently approved Paxil CR for the continuous treatment of premenstrual dysphoric disorder (PMDD) (September 2003), social anxiety disorder (October 2003) and the intermittent treatment of PMDD (February 2004). In January 2004, the Therapeutic Products Directorate of Health Canada approved Paxil CR for the treatment of central nervous system disorders, panic disorder and social anxiety disorder.
On March 4, 2005, GlaxoSmithKline announced that the FDA had halted supplies of Paxil CR due to manufacturing issues. SkyePharma provided the formulation of Paxil CR, but has no involvement in its manufacturing. GlaxoSmithKline announced the resupply of Paxil CR on June 27, 2005.
On April 28, 2005, the Company announced that it had entered into an amendment agreement with GlaxoSmithKline in respect of Paxil CR. Under the terms of the amendment agreement, GlaxoSmithKline made a one-time payment of approximately $10 million to the Company. In addition, the Company became entitled to an increase in the royalty rate from 3% to 4% on actual net sales of Paxil CR, with effect from March 4, 2005. As GlaxoSmithKline was unable to supply Paxil CR in the United
27
States between March 4, 2005 and June 27, 2005, when GlaxoSmithkline announced the resupply of Paxil CR in the United States, GlaxoSmithKline also agreed to pay SkyePharma the same level of royalty on GlaxoSmithKlines budgeted sales of Paxil CR from March 4, 2005, while the product remained off the market, subject to other terms of the agreement.
Xatral® OD is marketed in the United States (under the name Uroxatral®), Europe, Canada and certain countries in Africa, Asia and Latin America. It is a once daily Geomatrix formulation of alfuzosin used for the treatment of the functional symptoms of benign prostatic hyperplasia, a common condition in men over the age of 50, which was developed in conjunction with Sanofi-Synthelabo (now Sanofi-Aventis). In January 2000, Sanofi-Aventis announced that it had received the first batch of European marketing approvals for Xatral® OD. Uroxatral® was launched in the United States in November 2003. In March 2004, Sanofi-Aventis announced that it had begun to market Uroxatral® directly to primary care physicians in the United States. In addition to the United States, the product is now launched throughout Europe, Canada and certain countries in Africa, Asia and Latin America. Xatral® OD is now approved for a second indication, acute urinary retention, in more than 50 countries, including 24 in Europe. However Sanofi-Aventis is no longer pursuing U.S. approval for this indication.
Coruno® is a once per day Geomatrix formulation of molsidomine, currently marketed in Europe and used to treat angina pectoris, a common symptom of coronary heart disease. The Geomatrix controlled release technology in Coruno® enhances patient compliance and convenience by reducing the dosing requirement to once per day. Coruno® was developed in conjunction with the Therabel Group (Therabel) and was approved by the Belgian regulatory authorities in 2002 for marketing in Belgium. In April 2003, Therabel launched Coruno® in Belgium. Subsequently, Coruno® was approved and launched in Luxembourg.
Geomatrix Products in Development
The following table summarizes certain information on the Companys products under development that utilize Geomatrix technologies. The major products in development are discussed further below.
Product |
|
|
|
Modified |
|
Therapeutic Category |
|
Development Status |
|
Collaborative Partner |
Requip® Once-a-Day |
|
Yes |
|
Parkinsons Disease |
|
Phase III completed |
|
GlaxoSmithKline |
||
zileuton CR |
|
Yes |
|
Asthma/COPD |
|
Phase III completed |
|
Critical Therapeutics |
||
Lodotra |
|
Yes |
|
Inflammatory Conditions |
|
Phase III completed |
|
Nitec |
||
nisoldipine CR |
|
Yes |
|
Cardiovascular |
|
Phase I completed |
|
Sciele Pharma |
Requip® Once-a-day is a once daily dosage form of Requip® (ropinirole), which is an FDA-approved drug that is currently marketed, primarily in the United States and Europe by GlaxoSmithKline. As it is currently marketed, Requip® is an immediate release formulation administered three times daily and is prescribed for Parkinsons disease, a chronic progressive disease in which the degeneration of nerve cells in the brain eventually impairs the ability to control body movements. In December 2005, GlaxoSmithKline submitted Requip® Once-a-day for approval by U.S. and European regulatory authorities for the treatment of Parkinsons disease. This new once-daily oral formulation of Requip® incorporates the Companys Geomatrix oral controlled-release delivery technology, which is expected to improve patient convenience. The FDA has raised some administrative issues that were identified in the preliminary initial review and which led GlaxoSmithKline to withdraw the U.S. filing. The Company has been informed that it is the intention of GlaxoSmithKline to resubmit in late 2006. It is not expected that the European regulatory review process will be affected by FDA issues.
28
Zileuton is an FDA-approved drug for asthma and Chronic Obstructive Pulmonary Disease (COPD). A four times a day immediate-release version of zileuton was marketed by Abbott Laboratories (Abbott) as Zyflo® Filmtab (zileuton tablets). SkyePharma, together with Abbott, developed a controlled-release formulation of zileuton using its Geomatrix technology for twice daily administration. Abbott completed Phase III trials to use this product to treat asthma. In January 2004, SkyePharma announced an agreement with Critical Therapeutics Inc. (CTI), to whom Abbott sub-licensed zileuton, to collaborate on the further development of this formulation for the indications of moderate to severe asthma and COPD. Because of changes in the active pharmaceutical ingredient supplier and manufacturer, the formulation will need further in vivo (human) testing before an application may be filed. CTI announced in January 2006 that it had initiated two studies designed to support an NDA for the twice-daily version of Zyflo® (zileuton). These studies were recently completed and CTI expects to file the controlled release version with the FDA in the third quarter of 2006. Once approved by the FDA, CTI intends to market this product in the United States through its own specialist sales force.
Other Oral Products in Development
In addition to the products in the above table, the Company has a number of other Geomatrix projects in earlier stages of development. For a description of the development process, including definitions for development status stages, see Research and DevelopmentDevelopment Process for Brand-Name Pharmaceuticals.
Inhalation
The Company is developing advanced technologies to deliver medicines via a patients lungs without relying on chlorofluorocarbon CFC based propellants, which are considered environmentally harmful. The Company is working with two types of such inhalation systems:
· MDI TechnologiesMetered dose aerosol inhalers (MDI), the most widely used systems for inhalation drug delivery, have been in existence for more than 40 years and are primarily used to deliver asthma medications and other small molecule drugs to the lung, although significant advances have been made in recent years in the delivery of large molecule drugs, such as peptides and proteins, via the lung. MDI technologies rely on stable drug formulations with non-CFC propellants, hydrofluroalkanes (HFAs), to deliver the required therapy. In its MDI development work, the Company focuses on the formulation of drugs for use in MDIs manufactured by others.
· DPI TechnologiesDry powder inhaler (DPI) technology has emerged as an effective means of delivering asthma medications to the pulmonary system without the use of CFC propellants. Under the brand name SkyeHaler, the Company is developing a DPI that requires no propellant but instead is breath-actuated to deliver drugs in a fine powder suspension. In its dry powder inhaler development work, the Company focuses both on the development of the device and associated dry powder formulations.
In both its MDI and DPI development work, the Companys objective is to maximize the efficiency of the delivery system while addressing commercial requirements for reproducibility, formulation, stability, safety and convenience. The Company has assembled a team of researchers with substantial experience to develop proprietary techniques and methods that it believes will produce stable and reproducible dry powder and aerosol formulations. To achieve this goal, the Company is combining an understanding of lung biology, aerosol science, chemical engineering and mechanical engineering.
29
Approved Inhalation Products
There are two approved drugs that use the Companys Inhalation technologies
Product |
|
|
|
Indication |
|
Regulatory Approvals and Year of First Approval |
|
Collaborative Partner |
Foradil® Certihaler |
|
Asthma |
|
Switzerland (2005) |
|
Novartis |
||
Pulmicort® HFA-MDI |
|
Asthma |
|
Finland (2006) |
|
AstraZeneca |
Foradil® Certihaler. The Company has developed a DPI device with the compound formoterol pursuant to a collaborative agreement with Novartis. The Foradil® Certihaler has now been approved in 24 countries in Europe, the Middle East and Latin America. The product was launched in Germany and Switzerland in September 2005, but a batch recall from these markets was initiated in January 2006 because of concerns that accidental mishandling of the device had resulted in inaccurate dosing in a small number of cases. SkyePharma is collaborating with Novartis and the relevant health authorities to investigate the matter and the actions necessary before the product can be returned to the market. These are likely to include minor modifications of the device to prevent the occurrence of inaccurate dosing, while the key device characteristics are expected to be left unchanged. In the United States, Novartis received an approvable letter for the Foradil® Certihaler from the FDA in October 2003, a second approvable letter in December 2004 and a third approvable letter in April 2006 requiring device modification to prevent inaccurate dosing following accidental mishandling as a prerequisite for approval, in line with the European requirements. Novartis is currently working with the FDA on the most effective way to address its concerns.
Pulmicort® HFA-MDI . The Company has entered into a collaborative agreement with AstraZeneca to develop the next generation of AstraZenecas Pulmicort® (budesonide) HFAMDIs for the European market. Phase III clinical studies in Europe were completed in July 2004 and on June 28, 2005 AstraZeneca announced that it had filed an application for approval of this product for the first country in Europe. In February 2006, the product received approval in Finland, its first European market and other European approvals may be received in 2006. The currently available MDI formulation of Pulmicort® has been on the market since 1981 and uses CFCs as the propellant, which will now be replaced by the non-ozone depleting device using HFAs as the propellant. SkyePharma developed this new HFA-MDI formulation, which employs its proprietary formulation technology, and also conducted the clinical development programme for AstraZeneca.
Inhalation Products in Development
The table below summarizes inhalation products currently under development.
Product |
|
|
|
Therapeutic Category |
|
Development Status |
|
Inhalation System |
|
Collaborative Partner |
Flutiform |
|
Asthma/COPD |
|
Phase III in progress |
|
HFA-MDI |
|
Kos/SkyePharma |
||
QAB 149 |
|
Asthma/COPD |
|
Phase II completed |
|
DPI |
|
Novartis |
||
HFA-formoterol |
|
Asthma/COPD |
|
Phase II completed |
|
HFA-MDI |
|
SkyePharma |
Flutiform. The Company is developing Flutiform, a CFC-free metered-dose aerosol inhaler containing a fixed-dose combination of the long-acting bronchodilator formoterol with the inhaled steroid fluticasone for the treatment of asthma and COPD. A single delivery device containing two separate agents with complementary therapeutic roles (steroids are anti-inflammatory and address the underlying causes of asthma, whereas bronchodilators control the remaining symptoms of those attacks) brings convenience benefits for patients. In 2005, the Company completed phase II trials and a review of development activities with the FDA and European regulatory agencies and subsequently the Company initiated Phase III trials for Flutiform in February 2006. The product is on track for its target filing date
30
with the FDA in the second half of 2007 with U.S. market entry expected in early 2009. In May 2006 the Company announced that had entered into an agreement with Kos Pharmaceuticals to jointly develop Flutiform. Kos will have exclusive rights to market Flutiform in the United States and a right of first negotiation in Canada. SkyePharma could receive up to $165 million in milestone payments on the achievement of all regulatory and revenue targets (of which $25 million has been paid upfront) together with royalties on sales by Kos. SkyePharma remains in negotiations with potential partners for Europe and other markets around the world.
QAB 149 (indacaterol) is Novartis novel inhaled long-acting bronchodilator with rapid onset of action, which has completed Phase II development for both asthma and COPD. The QAB 149 development used the Companys Certihaler and related formulation technology in this second collaboration with Novartis. After the report of inaccurate dosing following accidental mishandling of the device, Novartis is currently revising future QAB 149 development plans. The Company cannot be certain that such plans will include the use of the Companys Certihaler.
Formoterol HFA-MDI is a formulation of the long-acting bronchodilator formoterol in an HFA-MDI. This product has completed Phase II development. However, because of the growing use of combination products for asthma and COPD, there is now a correspondingly diminishing market opportunity for single agent bronchodilators. The Company is undertaking a strategic review of the commercial viability of this product.
The Company also has a number of other projects at earlier stages of development utilizing its inhalation technology.
Topical
The Companys topical drug delivery technologies are primarily designed to maintain efficacy and localise delivery of drugs to the skin for the treatment of a variety of skin disorders. The Companys portfolio of topical drug delivery technologies consist of HA-based technologies, Crystalip, DermaStick and the ES-Gel system.
HA-based technologies are topical drug delivery technologies based on HA, a natural polymer, which is designed to maintain efficacy and localize the delivery of drugs to the skin for the treatment of a variety of skin disorders. The properties of HA enables drugs to potentially be targeted to and held at the site where the drug is needed. As a result, the Company believes formulations employing HA-based technologies may result in decreased systemic side effects or enhanced therapeutic effect.
The Company has one approved topical product:
Product |
|
|
|
Indication |
|
Regulatory Approvals and |
|
Marketing Partner |
Solaraze® |
|
Actinic Keratosis |
|
United Kingdom (1997) |
|
Shire Pharmaceuticals |
||
|
|
|
|
United States (2000) |
|
Bradley Pharmaceuticals |
Solaraze® is a topical gel used to treat actinic keratosis, a pre-cancerous skin condition caused by over-exposure to the sun. It is a formulation of HA and the non-steroidal anti-inflammatory drug diclofenac. Solaraze® has been shown to be an effective topical product for actinic keratosis. Compared with other actinic keratosis treatments, Solaraze® is non-invasive, non-scarring and is well tolerated by patients. Solaraze® is licensed to Bradley Pharmaceuticals Inc. in the United States and to Shire Pharmaceuticals PLC in Europe and Australia. It is currently marketed in the United States and various countries in Europe. Shire filed for approval in Australia in 2005 and in June 2006, Shire learned that the Australian regulatory agency has recommended rejection of the application. Shire is currently considering whether to appeal this decision.
31
Topical Products in Development
On April 29, 2004, the Company announced that it had licensed the rights to its dermatology assets, which account for substantially all of its topical drug delivery technologies, for those territories that are not covered by existing licenses, to Trigenesis Therapeutics, Inc. (Trigenesis). The rights relate to three marketed drugs, including Solaraze® for those territories not already licensed, rights to six pipeline products, including Hyclinda and Acyclovir, and a range of six proprietary and complementary delivery technologies, including HA-based technologies, Crystalip, Dermastick, ES-Gel, Dissocubes and Solid Lipid Nanoparticles. Under the agreement, Trigenesis is obligated to exploit the dermatology assets covered by the license and to continue the development of those drug candidates that are currently in the pipeline stage. Trigenesis has also assumed the majority of SkyePharmas existing obligations to third parties with respect to the development of these drug candidates. All rights granted by the Company to licensees under existing licenses remain unaffected by the agreement. In addition, the Company has retained the right to use the technologies subject to the license for the development of a number of new chemical entities in the dermatology area and, in certain cases, also for non-dermal applications. In May 2004, Trigenesis was acquired by Dr Reddys Laboratories Limited (Dr Reddys), an Indian pharmaceutical company. Dr Reddys assumed all the obligations of Trigenesis.
Solubilisation
Solubility of drugs is an essential factor for all drug delivery systems, independent of the route of administration. Poor solubility may lead to a range of problems including poor bioavailability, increased toxicity, variability of absorption when taken with food and poor efficacy. The Company believes that a large number of existing marketed drugs and newly synthesised compounds have solubility problems. The Companys solubilisation technologies consist of two complementary technologies, the nano-particulate and the Insoluble Drug Delivery (IDD) technologies. Both technologies aim to improve a drugs solubility by reducing the size of the particules. It has been demonstrated in laboratory testing that the saturation solubility of many drugs can be improved by reducing particle size below one micron in diameter. The Company is using its solubilisation technology platform to enhance the uptake and safety of water insoluble drugs across a broad range of therapeutic classes including anaesthetics, anti-cancer agents and immune suppressants. It is intended that the solubilisation technologies will be used to complement and enhance the Companys other drug delivery systems.
Approved Solubilisation Products
The Company has one approved solubilization product.
Product |
|
|
|
Indication |
|
Regulatory Approvals and |
|
Marketing Partner |
Triglide® |
|
Cardiovascular |
|
United States (2005) |
|
Sciele Pharma |
Triglide® is an IDD formulation of fenofibrate which the Company was initially developing in partnership with an undisclosed pharmaceutical company. During 2003, the Company and its partner re-negotiated the terms of their agreement and the Company re-acquired rights to the product for an unspecified amount. Triglide® is a lipid-lowering agent launched by Abbott under the trade name Tricor® in the United States in 1998. The IDD formulation is a lower dose product providing blood levels similar to the original 200mg Tricor® product and that can be taken with or without food. On May 17, 2004, the Company announced an exclusive agreement with First Horizon Pharmaceutical Corporation, now renamed Sciele Pharma, Inc. (Sciele Pharma) through which the Company granted Sciele Pharma the exclusive U.S. marketing and distribution rights for Triglide®. Following FDA approval in May 2005, Sciele Pharma launched Triglide® on the U.S. market in July 2005.
32
Solubilization Products in Development
The Company granted an exclusive license to the United States and Canadian marketing and distribution rights for Propofol IDD-D to Endo. Propofol IDD-D is our novel formulation of propofol, a widely-used injectable anaesthetic and sedative. Our formulation was designed to avoid the need for a preservative and to be suitable for long-term use in intensive care units. Although this product satisfactorily completed Phase II trials in 2004, the Phase III trial has not yet commenced and in April 2006 we agreed with our North American partner Endo to terminate the joint development of Propofol IDD-D as the product was unlikely to achieve its target profile. As a result, the Company believes this product has limited commercial potential.
The Company has two injectable technologies
DepoFoamThe Companys primary injectable technology is DepoFoam. DepoFoam consists of lipid-based particles composed of hundreds to thousands of discrete water-filled chambers containing the encapsulated drug, with each chamber separated from adjacent chambers by a lipid membrane. The particles are suspended in saline for injection. DepoFoam formulations can be delivered into the body by a number of routes, including under the skin, within muscle tissue, into brain and spinal fluid, within eyes, within joints and within the abdominal cavity. The Company has combined many drugs with DepoFoam in the laboratory and clinic and has two commercialized products based on this technology. Clinical studies show that DepoFoam techonologies often achieve sustained controlled release of the drugs. This feature allows the Company to develop new formulations of drug products aimed at treating different diseases and symptoms or allows for more convenient administration by reducing the number or frequency of injections. The drug candidates include drugs that have already been shown to be useful or potentially useful in humans, as well as new drugs in development at other pharmaceutical companies, which may potentially benefit from DepoFoam. The Company does not conduct research and development to discover new drugs to use in combination with DepoFoam.
BiosphereThe Companys second sustained-release injectable technology is the Biosphere drug delivery system. The Biosphere drug delivery system provides sustained-release of injectable proteins and peptides. The technology encapsulates the drug substance in highly purified starch in microscopic spheres that are then coated with a copolymer of lactic and glycolic acid. After injection, the coating and core erode and the drug content is released over a controlled period that can range from days to months. In contrast with conventional microspheres, the coating used in Biosphere does not contain any drug so there is a low burst even at high drug loadings. In 2003, the Company announced that the Biosphere technology had been successfully used in pre-clinical studies to deliver a protein drug human growth hormone over an extended period of time. The product has now successfully completed Phase I trials. In addition to the human growth hormone, the Company is also evaluating Biosphere formulations of other proteins and peptides.
Approved Injectable Products
The following table summarizes certain information on the Companys two approved products that utilize its injectable technologies.
Product |
|
|
|
Indication |
|
Regulatory Approvals and |
|
Marketing Partner |
DepoCyt® |
|
Oncology |
|
United States (1999) |
|
Enzon |
||
|
|
|
|
Europe (2001) |
|
Mundipharma |
||
DepoDur |
|
Acute Pain |
|
United States (2004) |
|
Endo |
33
DepoCyt® combines the Companys DepoFoam technology with cytarabine, a drug used to treat neoplastic meningitis from lymphomas and solid tumors. It is currently marketed in North America by Enzon and in the European Union and certain other countries in Europe by Mundipharma for the treatment of lymphomatous meningitis. DepoCyt® was developed in collaboration with Chiron Corporation (Chiron) in the United States and, until June 2000, with Pharmacia & Upjohn S.p.A., an affiliate of Pharmacia Corporation. We have completed a Phase IV clinical trial required by the FDA and have submitted the results to the FDA. We have also filed with the EMEA in Europe for the additional indication of the most common form of neoplastic meningitis, associated with solid tumours. The file has been withdrawn as the EMEA needed additional clinical data to make a positive risk-benefit assessment.
DepoDur (previously referred to as DepoMorphine) has been developed for the control of moderate to severe post-operative pain. DepoDur is given as a single epidural injection in the peri-operative period and provides pain relief for up to 48 hours following surgery. The Companys U.S. marketing partner Endo Pharmaceuticals launched DepoDur in December 2004. The product is still in the launch phase but has now been accepted on more than 400 hospital formularies, the first gateway to routine hospital use. In the U.K., we have recently been granted approval for DepoDur by the U.K. Committee on Safety of Medicines, the CSM. This will be used as the basis for seeking approval throughout the European Union under the EUs Mutual Recognition procedure. Zeneus Pharmaceuticals, SkyePharmas European licensee for DepoDur, announced in December 2005 that it had reached agreement to be acquired by the U.S. company Cephalon Inc. SkyePharma has regained the European rights for DepoDur and is now seeking a new sales and distribution partner for the EU and other territories outside North America.
Injectable Products in Development
The following table summarizes certain information on the Companys products under development that utilize its injectable technologies. The major products in development are discussed further below.
Product (Active Compound) |
|
|
|
Therapeutic category |
|
Development Status |
|
Collaborative Partner |
DepoBupivacaine |
|
Post surgical/post injury pain |
|
Phase II completed |
|
SkyePharma/Maruho |
||
Psoraxine |
|
Psoriasis |
|
Phase II completed |
|
Astralis |
||
HgH |
|
Growth Disorders |
|
Phase I completed |
|
SkyePharma |
||
Interferon alpha-2b |
|
Anti-viral/Oncology |
|
Pre-clinical |
|
SkyePharma |
||
GCSF |
|
Oncology |
|
Pre-clinical |
|
SkyePharma |
DepoBupivacaine is a DepoFoam formulation of the local anaesthetic bupivacaine, for the treatment of regional pain. In April 2005, the Company entered into a development and licensing agreement for DepoBupivacaine with MundiPharma for Europe and certain other international markets excluding the United States and Japan. In November 2005, SkyePharma announced that it had entered into an exclusive marketing and distribution agreement with Maruho Company Limited (Maruho) for Japan.
The product successfully completed Phase II clinical trials in 2005. In June 2006, the Company completed negotiations with Mundipharma the result of which is that the Company will reacquire the rights for the marketing and distribution of DepoBupivacaine and the clinical data from the Phase II trials of DepoBupivacaine for $ 5 million. Endo Pharmaceuticals, our North American partner for DepoDur, had a right of first negotiation for commercial rights to DepoBupivacaine for North America, but has now relinquished this right. The reacquisition of rights from Mundipharma and the relinquishment of rights by Endo means that the Company can now offer unrestricted global rights to DepoBupivacaine (outside Japan) to parties interested in acquiring the injectables business. Maruho will
34
conduct the clinical development of DepoBupivacaine required for regulatory approval in Japan at its own cost.
The Company is also evaluating, in conjunction with undisclosed corporate partners, DepoFoam and Biosphere formulations of several additional compounds, including small molecule chemical compounds and macromolecule biologics.
Collaborative Arrangements
The Company has collaborative arrangements with each of its pharmaceutical partners, the terms of which vary considerably. Pursuant to these arrangements, the Companys partners typically fund all or a large part of the research and development expenses incurred in the development of new formulations of their products. This funding typically takes the form of a flat fee for the Companys research and development efforts, an agreed research and development budget charged at an hourly rate, or milestone payments on signing and on the achievement of technical or commercial milestones. Some agreements have involved equity investments in the Company by the Companys partners. In negotiating contracts with its partners, the Companys strategy generally has been to cover its costs in the research and development process. Substantially all potential profits are expected to be generated by royalty payments or manufacturing fees for successfully developed and marketed products. In some cases, milestone payments may be deducted from future royalty payments for successfully developed and marketed products.
In return the Company gives each of its partners an exclusive license to market the products incorporating the Companys technologies. In some cases the licenses are worldwide. In others they are limited to specific territories. In most cases, partners are free to sublicense the technologies, although the Companys consent may be required and royalties on all sales must be paid to the Company. In addition, the majority of the collaborative agreements do not restrict the Company from developing formulations of competitive products. In some cases, however, the Company will agree not to develop formulations of specified compounds for an agreed period of time.
The Companys collaborative partners frequently take responsibility for conducting clinical trials and for preparing and pursuing all necessary regulatory approvals, although more recently the Company has taken responsibility for managing clinical trials in some collaborations. The Company may assist its partners in the conduct of such trials and the preparation of regulatory filings. Its partners may ultimately control the process, including the selection of the jurisdictions in which regulatory approval will be sought, if at all.
The collaborative agreements frequently do not obligate the partners to market any successfully developed and approved products. The Company does not have any control over whether and to what extent a partner will elect to commercialise a product. A client may choose not to market a product for reasons wholly independent of the Companys technologies. In most cases, if a client does not proceed to market the product once it has been successfully formulated and approved, the Company will not receive any additional income in respect of the product. In some more recent collaborations, however, contracts have included certain commitments from the Companys partners to use specified minimum resources to market the product or to pay a minimum royalty in lieu of sales of the product or failing that to return the product rights to the Company.
During the formulation and development stages, the Companys partners are generally free to terminate the collaborative relationship at any time and for any reason after providing the Company with a notice period.
35
The Companys key license, development, marketing and distribution relationships are set out in the table below.
Product |
|
|
|
Collaborative Partner |
|
Technology Platform |
|
Territory Covered |
Paxil CR |
|
GlaxoSmithKline |
|
Oral |
|
Worldwide |
||
Xatral® OD |
|
Sanofi-Aventis |
|
Oral |
|
Worldwide |
||
Coruno |
|
Therabel |
|
Oral |
|
Worldwide |
||
Requip® |
|
GlaxoSmithKline |
|
Oral |
|
Worldwide |
||
Zileuton CR |
|
Critical Therapeutics |
|
Oral |
|
United States |
||
Foradil® Certihaler |
|
Novartis |
|
Inhalation |
|
Worldwide |
||
Pulmicort® HFA-MDI |
|
AstraZeneca |
|
Inhalation |
|
Worldwide (except United States) |
||
Flutiform |
|
Kos |
|
Inhalation |
|
United States |
||
DepoCyt® |
|
Enzon |
|
Injectable |
|
United States and Canada |
||
DepoCyte® |
|
Mundipharma |
|
Injectable |
|
E.U. and certain other |
||
DepoDur |
|
Endo |
|
Injectable |
|
United States and Canada |
||
DepoBupivacaine |
|
Maruho |
|
Injectable |
|
Japan |
||
Triglide® |
|
Sciele Pharma |
|
Solubilisation |
|
United States |
Other Significant Collaborative Arrangements
In December 2000, SkyePharma entered into an agreement with Paul Capital Royalty Acquisition Fund (Paul Capital). Under the agreement, Paul Capital provided a total of $30 million between 2000 and 2002, in return for the sale of a portion of potential future royalty and revenue streams from DepoDur, Xatral® OD, Solaraze® and DepoCyt®. The monies were used to fund the clinical development of DepoDur. Between January 2003 and December 2014, Paul Capital will receive 15% of the annual royalties and revenues from the stated products up to an agreed ceiling. Once the predetermined ceiling is reached, the percentage participation will fall to 3% for the remainder of the period until December 31, 2014.
In March 2002, SkyePharma entered into a second agreement with Paul Capital. Under the terms of the agreement, Paul Capital paid SkyePharma $30 million during 2002 and 2003, in return for a portion of the future royalty and revenue streams from nine products in the Companys pipeline. The monies have been used principally to fund the clinical development of Propofol IDD-D and HFA-formoterol. The nine products referred to are Propofol IDD-D and HFA-formoterol, the lipid-lowering drug Triglide®, an anti-cancer agent busulfan, an intravenous formulation of the antibiotic oxytetracycline, oral budesonide to treat inflammatory bowel disease, HFA-budesonide and Foradil®, for the treatment of asthma, and the anti-depressant Paxil CR. Between January 2002 and December 2015, Paul Capital will receive between 4% and 20% of the annual royalties and revenues from the total of nine products. The 20% rate applies first. The percentage then falls, when an agreed return is achieved, to 12.5% until a second ceiling is reached, before falling to 4% for the remainder of the period until December 31, 2015. During 2002 and 2003, the 20% rate was reduced based on the percentage of the total $30 million already funded. Also under the terms of these agreements, Paul Capital has been issued warrants carrying rights to subscribe for 5 million SkyePharma Ordinary Shares at an exercise price of 73.75 pence.
The Companys research and development activities are conducted in Muttenz, Switzerland and in San Diego, United States. As of December 31, 2005, the Company had 282 employees at these two facilities, the majority of whom were engaged in research and development and manufacturing. In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and
36
concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectables business in San Diego.
The Company conducts research and development both with respect to its own internally funded products as well as for third parties. The Company accounts for costs incurred in conducting internal research and development activities as research and development expenses and for costs incurred on development work for third party customers as cost of sales. The Companys self-sponsored research and development costs are expensed as incurred.
The Company records amounts received from third parties under the Companys contract development arrangements within turnover, as contract development income. Contract development income represents amounts invoiced to customers for services rendered under development contracts or for milestone payments in accordance with the contract terms. Such amounts are only treated as revenue when the services have been rendered or the specified milestone has been met. Certain refundable income is treated as deferred income until the Company has no further obligations to make refunds. The Company generally attempts to break even on its development work for third party customers. Therefore, product development activities do not currently have a significant impact on the Companys operating profit/(loss).
The Companys development processes are described below. Specific development steps for a product may vary or be unnecessary depending on a number of factors, including the drug delivery technology used and whether the product incorporates an active ingredient already available on the market.
Development Process for Brand Name Pharmaceuticals
In order to obtain approval of a new drug or a new formulation of an existing drug it is necessary to undertake a series of tests and trials. Specific development steps for a product may vary or be unnecessary depending on a number of factors, including the drug delivery technology used and whether the product incorporates an existing marketed active ingredient. A typical development process may include the following series of tests and trials:
Preclinical tests encompass the laboratory evaluation of a new pharmaceutical, its chemistry, formulation and stability, as well as animal studies to assess its potential safety and efficacy. Following the conclusion of preclinical tests, the results of these studies, which have to demonstrate that the pharmaceutical delivers sufficient quantities of the drug to the bloodstream to create the desired therapeutic results, are submitted to the relevant regulatory authority, which must be approved before human clinical trials may begin.
Human clinical trials are typically conducted in three sequential phases:
· Phase I. During this phase, the drug is initially introduced into a relatively small number of healthy humans or patients and is tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion.
· Phase II. This phase involves studies in a limited patient population to identify possible adverse effects and safety risks, to determine the efficacy of the drug for specific targeted diseases or conditions, and to determine dosage tolerance and optimal dosage.
· Phase III. When Phase II evaluations demonstrate that a dosage range of the drug is effective and has an acceptable safety profile, Phase III trials are undertaken to further evaluate dosage, clinical efficacy and test for safety in an expanded patient population at geographically dispersed clinical sites.
· Regulatory Filing. The Company alone, or in collaboration with its partner, or its partner manages regulatory activities during product development phases. These activities include developing regulatory strategies, information submissions and meetings with health authorities and preparation
37
of marketing approval applications. Post-approval product development may necessitate additional regulatory filings.
Patents and Proprietary Rights
The Company believes that patent and other intellectual property protection of its drug delivery and formulation technologies is critical to its business and that its future performance will depend in part on its ability to obtain patents, maintain confidential and trade secret information and to operate without infringing the intellectual property rights of others.
Oral Controlled Release Technology
The Company has two patent families in respect of its core Geomatrix technologies. The first patent family was issued in Australia, New Zealand, Italy, Europe, Japan, the United States and Canada. It expired in 2002 in Australia and New Zealand, 2005 in Italy, and will expire in 2006 in the rest of Europe, Japan and the United States, and in 2009 in Canada. The second patent family relating to the Companys Geomatrix technologies was granted in Italy, the United States and Europe, Canada and Japan. These patents expire between 2009 and 2012.
In addition, the Company holds several other patents related to its oral controlled release technology, and has applications filed in markets including Europe, the United States, Japan, Canada, Australia and New Zealand, which continue to protect the technology to 2018. These patents and applications cover the variety of different tablet formulations containing an active drug core and various surface coatings covering the core. These cores and coatings contain excipients that enable a variety of release profiles to be achieved. Later applications cover recent innovations and/or improvements to the original inventions.
In total, the Company has 175 patents protecting the Geomatrix technology, which represents 27 patent families. The Company continues to file additional patent applications relating to oral drug delivery technologies in order to secure protection for its activities in this area.
Inhalation Technology
The Company has 17 patent families in respect of its inhalation technology. One family covers SkyeHaler itself as well as several of the structural elements and features incorporated therein, and has been granted in the United States, Europe, Japan and certain other countries. Each of these patents expires no earlier than 2015. Other patent families relate to a dry powder, for use with the Dry Powder Inhalers.
The Company has, together with other companies working in the same area, been involved in several European patent oppositions related to the use of environmentally friendly HFA as propellants. Of these oppositions four have been settled and the remaining four are in various stages within the European Patent Office. There are currently six oppositions in which SkyePharma is participating in relation to various aspects of inhalation technologies. As with all contentious proceedings, the outcome of patent oppositions is uncertain and, if negative, could have an adverse effect on the Companys business.
Topical Technology
The Company owns a wide range of intellectual property rights covering its topical technology. Patents and applications covering many and varied uses of hyaluronic acid have been filed throughout the world. Following these filings, patents have been granted in the United States, Europe, Japan and certain other countries expiring between 2010 and 2013. On 29 April 2004, the Company announced that it had licensed the bulk of its Topical Technology to Trigenesis.
38
Solubilisation
The Company has rights to a total of 7 patent families related to its solubilisation technology. The Company owns two patent families covering solid lipid nanoparticles and nano-suspensions, each of which are useful for drug delivery. These two patent families, as well as applications filed, protect the Companys technologies in the area of solid lipid nanoparticles and nano-suspensions in the United States, Europe, Japan and certain other countries until 2015. The Company also has an exclusive license under two further patent families: one relating to solid polymer nano-particulate technology and the other to further developments in the areas of solid lipid nano-particles and nano-suspensions.
In addition, the Company owns a large portfolio of patents and patent applications covering three broad patent families relating to:
(i) Lipid stabilised microparticle technology (where the drug is a solid particle);
(ii) Lipid stabilised microdroplet technology (where the drug is a liquid); and
(iii) Omega-3 oil stabilised drug technology, which is useful for drug delivery.
The Companys solubilisation technology is protected by numerous patent and patent applications worldwide including: 15 patents in the United States and 70 corresponding patents in countries outside the United States. In addition, the portfolio contains many pending applications, including 23 patent applications in the United States, 23 regional (European and PCT) patent applications and 35 applications in other countries.
Injectable Technology
The Company owns a large portfolio of patents relating to the DepoFoam delivery technology in the United States, Europe, Japan and certain other countries. The majority of these patents will continue in force until 2014. Additional filings of patent applications have been made for improvements of the initial technology and for innovative technology relating to this subject matter in the United States, Europe, Japan and certain other countries. In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectables business interests.
In addition, through a prior agreement entered into by SkyePharma Inc. with the Research Development Foundation (RDF), RDF granted certain rights, on an exclusive basis, relating to the DepoFoam technology to SkyePharma Inc. Under the agreement SkyePharma Inc. is obliged to prosecute certain patent applications and maintain issued patents relating to the licensed intellectual property. RDF retains the right to terminate the agreement or to convert the exclusive nature of the rights granted under the agreement, into a non-exclusive license in the event that SkyePharma Inc. does not satisfy its contractual obligations including making certain minimum annual payments. Additional termination events include bankruptcy and a material breach of the agreement, which is not remedied within a specified period. The termination of this agreement or the conversion to a non-exclusive agreement would have a material adverse effect on the Company. In April 2004, the Company entered into an amendment agreement with RDF pursuant to which certain commercial terms of the RDF agreement were re-negotiated. As part of the re-negotiation of these terms, 3.25 million Ordinary Shares of the Company were issued to RDF.
39
The Company owns a wide range of intellectual property rights covering its Biosphere technology. Patent applications have been filed and issued in the United States, Europe, Japan and certain other countries. The Company owns 12 patent families in respect of its Biosphere technology. The later patent filings will offer protection out until 2023.
Patent Protection
There can be no assurance that the Company will be issued any additional patents or that if any patents are issued, they will provide the Company with significant protection or will not be challenged by third parties asserting claims against the Company concerning its existing products or with respect to future products under development by the Company. The Company, from time to time, may receive notification of alleged infringements. The Company may not, in all cases, be able to resolve such allegations through licensing arrangements, settlement or otherwise. Furthermore, the Company anticipates that any attempt to enforce its patents would be time consuming and costly. Moreover, the laws of some foreign countries do not protect the Companys proprietary rights in the products to the same extent as does the law of the United States.
Manufacturing in Europe
Manufacturing operations in Europe take place at the Companys Lyon facility in France and Muttenz facility in Switzerland. In Lyon the Company has an approximately 17,000 square meter (183,000 square feet) pharmaceutical manufacturing and production facility and an approximately 2,400 square metre (25,850 square feet) adjoining office complex. In Muttenz the Company has a 11,700 square metre (125,942 square feet) facility. The Company presently manufactures four Geomatrix products, Madopar DR in its Muttenz facility and Diclofenac-ratiopharm-uno, Xatral® OD and Coruno in its Lyon facility. In addition the Company manufactures one other oral product, Triglide®, based on its solubilization technology, at its Lyon facility. The Company produces bio-batches for its internal development products and its collaborative partners in both facilities.
The Lyon facility was designed and built for drug production in 1993 by American Cyanamid (subsequently part of AHP) but was used instead for packaging activities. Under the terms of the Companys 1997 acquisition of the facility from AHP, the Companys manufacturing activities were gradually transferred into the facility and the Company also packaged certain pharmaceutical products and other products (Contract Products) on behalf of certain subsidiaries of AHP. The facility is in compliance with cGMP with respect to packaging operations and it has European regulatory approval to package the Contract Products.
The Company completed its Geomatrix manufacturing suite in the Lyon facility at a capital cost of approximately £7.1 million. This facility is being used to manufacture oral and solubilisation products for collaborative partners and for the Company. The facility enables the Company to manufacture its own products in addition to contracting with third parties. In 2004, the plant expanded its oral manufacturing facilities to include two large-scale microfluidisers for the production of Triglide®. Scale-up to the final commercial scale was completed in the second half of 2004.
Manufacturing of Coruno started in April 2003, Xatral® OD in March 2004 and Triglide® in May 2005. The contract for manufacturing Xatral® OD is expected to terminate in December 2006. The FDA has inspected the Lyon facility in respect of four products; Dilacor XR, Coruno, Xatral® OD and Triglide®. All the pre-approval inspections have been passed. There can be no assurance, however, that the Lyon facility will ultimately be found to be in compliance with cGMP or other regulatory requirements for the purposes for which the Company plans to use the facility. Failure to comply could result in significant
40
delays in the Companys planned manufacturing efforts. The Company also could incur significant additional expense in bringing the facility into compliance with cGMP or other regulatory requirements.
The Company expanded its operations at the Lyon facility to include production activities for dry powder inhaler products pursuant to the Novartis development contract at a capital cost to date of approximately £8.1 million. In December 2003, the FDA approved the facility for the commercial filling of the Foradil® Certihaler, which commenced in 2005 in preparation for launch in some of the European countries where the product is approved. The dry powder inhaler (SkyeHaler) is manufactured by a Swiss plastic contract manufacturer, Riwisa AG. Final assembly and filling of the SkyeHaler with the powder blend containing formoterol fumarate takes place in the Lyon facility. The product is then released for marketing at the Lyon facility and delivered to Novartis for final packaging and distribution. Following the Foradil® Certihaler batch recall in January 2006, manufacturing of the product has been suspended pending device modification to prevent inaccurate dosing following accidental mishandling.
Due to EMEA requirements to retest drugs being imported into Europe, retesting and packaging operations were established at the Lyon facility during 2003 and 2004 for DepoCyt® supplies for Europe under the Mundipharma marketing and distribution agreement.
Manufacturing in North America
DepoFoam manufacturing operations take place at the Companys facilities in San Diego, California. The Company currently manufactures two DepoFoam products for commercial sale at its facilities in San Diego: DepoCyt® and DepoDur. In late 2005 and early 2006, the Board of Directors of the Company conducted a full strategic review and concluded that in the interests of achieving sustainable profitability in the near term, and in order to improve the Companys cash flow position, the Company should concentrate on oral and inhalation products, and divest its injectables business interests.
Manufacturing for DepoCyt® takes place in an approximately 2,020 square metre (21,746 square feet) facility built for this purpose. This facility complies with cGMP and is approved for commercial drug manufacturing by the FDA and EMEA.
Commercial manufacturing for DepoDur takes place in an approximately 7,600 square metre (82,000 square feet) facility housing production, administrative and research and development activities. This facility complies with cGMP and is approved for the commercial manufacture of DepoDur. Clinical trial materials are also manufactured in this facility. Prior to marketing any drugs (including DepoCyt® and DepoDur) outside countries where approval has been gained, the Company will need to meet applicable regulatory standards, achieve prescribed product quality and reach necessary levels of production of such products.
Manufacturing Partners
While the Company has its own manufacturing sites for Geomatrix inhalation (dry powder products) and DepoFoam manufacturing, for the manufacture of certain of its existing products, and certain of those currently in development, the Company will depend at times on manufacturing partners.
Under the terms of the development and commercialization agreement with Endo for DepoDur and Propofol IDD-Dä signed in December 2002, in respect of the United States and Canada, the Company is primarily responsible for the clinical development of the products up to final FDA approval and for product manufacture, including all associated costs. The Company also agreed to qualify and obtain final regulatory approval for a second manufacturing site for DepoDur, either internally or through a third party manufacturing partner, within a specified period from the date of first commercial sale. In April 2006 we agreed with Endo to terminate the joint development of Propofol IDD-D as the product was unlikely to achieve its target profile.
41
The Company does not have commercial scale manufacturing capabilities for the HFA-MDI products, Pulmicort® , Formoterol and Flutiform. AstraZeneca is responsible for the manufacture of Pulmicort® . The Company has entered into a contract for clinical supplies of Flutiform with a third party contract manufacturer and is currently in negotiation with the same manufacturer for the production of commercial supplies.
The Company and its collaborative pharmaceutical company partners rely on certain suppliers of key raw materials. Certain of those materials are purchased from single sources and others may be purchased from single sources in the future. Although the Company has no reason to believe that it and its collaborative pharmaceutical company partners will be unable to procure adequate supplies of such raw materials on a timely basis, and at commercially reasonable rates, disruptions in supplies, including delays due to the inability of the Companys pharmaceutical company partners, the Company or its manufacturers to procure raw materials, would have a material adverse effect on the Companys business.
Regulatory requirements for pharmaceutical products tend to make the substitution of suppliers costly and time-consuming. The inability to develop alternative sources could have a material adverse effect on the Companys ability to manufacture and market its products.
One of the DepoFoam Injectable products, DepoDur, has morphine sulphate as its active ingredient. Morphine sulphate is classified as a Scheduled Drug by the United States Drug Enforcement Agency (DEA). The DEA has determined that these drugs have a high potential for abuse and could lead to severe psychological or physical dependence. The DEA controls the national production and distribution of certain Scheduled Drugs in the United States by allocating production quotas based, in part, upon the DEAs view of national demand. SkyePharma Inc. has a DEA license to use morphine sulphate in its research and manufacturing of DepoDur. While the Company expects that adequate quantities of the drug will be available to it to meet future research and commercial requirements, there can be no assurance to that effect.
The Company is not involved in the direct marketing of products formulated with its technologies. The Company depends on its collaborative partners for such marketing and sales. The majority of the Companys partners are not obligated to market products incorporating its technologies, even if such products are successfully developed and approved. However, in some more recent collaborations, contracts have included certain commitments by the Companys partners to market products developed in collaboration with the Company.
The pharmaceutical industry is highly competitive and is affected by new technologies, governmental regulations, health care legislation, availability of financing and other factors. Many of the Companys competitors have longer operating histories and greater financial, marketing and other resources than the Company.
The Company is and will continue to be subject to competition from numerous other entities that currently operate, or intend to operate, in the pharmaceutical industry. These include companies that are engaged in the development of controlled-release technologies and products, as well as other pharmaceutical manufacturers that may decide to undertake in-house development of these products.
As the pharmaceutical industry continues to consolidate and as pressures increase for cost-effective research and development, some pharmaceutical companies have reduced and may continue to reduce their funding of research and development. Competition for limited client financing may therefore
42
increase, and this competition could include the clients internal research and development programs, other drug delivery programs and other technologies and products of third parties.
All drugs and medical devices, including the Companys products under development, are subject to extensive regulation in the United States and Europe, the Companys two principal markets. In the United States, the primary regulatory body is the FDA, although to a lesser extent state and local authorities are also involved in the regulatory process. In Europe there are two regulatory systems. There is a European Union system that is the responsibility of the EMEA. In addition, each country has its own regulatory agency. In both the United States and Europe, the applicable regulations govern or influence the development, testing, manufacture, safety, labelling, storage, record keeping, approval, advertising, promotion, sale and distribution of prescription pharmaceutical products. Pharmaceutical manufacturers are also subject to certain record keeping and reporting requirements, establishment registration and product listing and agency inspections.
United States
The federal Food, Drug and Cosmetics Act (FDCA), the Public Health Services Act, the Controlled Substances Act and other federal statutes and regulations govern or influence all aspects of the Companys business. Non-compliance with applicable laws and regulations can result in fines and other judicially imposed sanctions, including product seizures, injunctive actions and criminal prosecutions. In addition, administrative or judicial actions can result in the recall of products, and the total or partial suspension of the manufacturing of products, as well as the refusal of the government to approve pending applications or supplements to approved applications. The FDA also has the authority to withdraw approvals of drugs in accordance with statutory due process procedures.
FDA approval is required before any dosage form of any new unapproved drug or new indication of use for an existing drug, including a generic equivalent of a previously approved drug, can be marketed. All applications for FDA approval must contain information relating to evidence of safety and efficacy or bio-equivalence to a listed reference drug, product formulation, stability, manufacturing processes, packaging, labelling and quality control.
NDA Process
A New Drug Application (NDA) is submitted to the FDA to obtain approval of a new drug, new label indication of an existing drug, or a new formulation of an existing drug and must contain complete chemistry, manufacture and control (CMC), pre-clinical, and clinical safety and efficacy data or a right of reference to such data. Before dosing an investigational drug (new chemical entity or new formulation) in healthy human subjects or patients may begin, stringent government requirements for pre-clinical data must be satisfied. The pre-clinical data, typically obtained from studies in animal species, as well as from laboratory studies, are submitted in an Investigational New Drug application (IND), or its equivalent in countries outside the United States where the relevant clinical trials are to be conducted. The pre-clinical data must provide an adequate basis for evaluating both the safety and the scientific rationale for the initiation of clinical trials.
Clinical trials are typically conducted in three phases: Phase I, II and III. A description of each of these phases of development is included in Research and DevelopmentDevelopment Process for Brand-Name Pharmaceuticals. Data from pre-clinical testing and clinical trials are submitted to the FDA as an NDA for marketing approval. The process of completing clinical trials for a new drug is likely to take several years and require the expenditure of substantial resources. Preparing an NDA or marketing authorization application (MAA) involves considerable data collection, verification, analysis and expense, and there can be no assurance that approval from the FDA will be granted on a timely basis, if at
43
all. The approval process is affected by a number of factors, primarily the risks and benefits demonstrated in clinical trials as well as the severity of the disease and the availability of alternative treatments. The FDA may deny an NDA or MAA if the regulatory criteria are not satisfied, or such authorities may require additional testing or information.
Even after initial FDA approval has been obtained, further studies, including Phase IV post-marketing studies, may be required to provide additional safety data and will be required to obtain approval for the use of a product as a treatment for clinical indications other than those for which the product was initially tested. Also, the FDA or other regulatory authorities require post-marketing reporting to monitor the safety of the approved drug. Results of post-marketing programs may limit or expand the further marketing of the products. Further, if there are any modifications to the drug, including changes in indication, manufacturing process or labelling or a change in manufacturing facility, an application seeking approval of such changes must be submitted to the FDA or other regulatory authority. Additionally, the FDA regulates post-approval promotional labelling and advertising activities to assure that such activities are being conducted in conformity with statutory and regulatory requirements. Failure to adhere to such requirements can result in regulatory actions which could have a material adverse effect on the Companys business, results of operations and financial condition.
The FDCA provides for NDA submissions that may rely in whole or in part on publicly available clinical data on safety and efficacy under section 505(b)(2) of the FDCA. The Company and its collaborative partners may be able to rely on existing publicly available safety and efficacy data in filing NDAs for extended-release products when such data exist for an approved immediate-release version of the same chemical entity. However, there is no guarantee that the FDA will accept such applications under section 505(b)(2), or that such existing data will be publicly available or useful. Additionally, under the Prescription Drug User Fee Act of 1992 (the PDUFA), all NDAs require the payment of a substantial fee upon filing, and other fees must be paid annually after approval. Under the PDUFA, there are circumstances when waivers may be granted to the payment of user fees. No assurances exist that, if approval of an NDA is required, such approval can be obtained in a timely manner, if at all.
Other Regulation
The Prescription Drug Marketing Act (PDMA), which amends various sections of the FDCA, imposes requirements and limitations upon drug sampling and prohibits states from licensing wholesale distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include, among other things, state licensing of wholesale distributors of prescription drugs under federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations of these and other provisions. Nevertheless, failure by the Companys distributors to comply with the requirements of the PDMA could have a material adverse effect on the Companys business, results of operations and financial condition.
Manufacturers of marketed drugs must comply with cGMP regulations and other applicable laws and regulations required by the FDA, the Environmental Protection Agency, the DEA, the HPB in Canada, the EMEA in the European Union and other regulatory agencies. Failure to do so could lead to sanctions, which may include an injunction suspending manufacturing, the seizure of drug products and the refusal to approve additional marketing applications. The Company seeks to ensure that any third party with whom it contracts for product manufacturing will comply with cGMP. The FDA conducts periodic inspections to ensure compliance with these rules. However, there can be no assurance that any such third parties will be found to be in compliance with cGMP standards. Any such non-compliance could result in a temporary or permanent interruption in the development and testing of the Companys planned products or in the marketing of approved products, as well as increased costs. Such non-compliance could have a material adverse effect on the Companys business, results of operations and financial condition. SkyePharma Inc.s
44
manufacturing facility located in San Diego, California is regulated by the State of California, Department of Health Services, Food and Drug Branch, and the DEA.
European Union Regulation
The European drug registration system is based on co-operation between the EMEA, established in London, and competent national authorities of the member states of the European Union.
A national approval process exists for each country, but this route of drug approval is used less frequently as each country negotiates separately on the merits of the information included in the registration dossier, the product claim or indication, and the text that appears on the product label. In 1995, two additional registration procedures were enacted.
The first of these is a centralized procedure available for new chemical entities, innovative products and delivery systems, and compulsory for biologically medicinal products derived from biotechnology, and available at the request of companies for other innovative new products. Under this procedure Marketing Authorization Applications (MAAs) are submitted to the EMEA. At the conclusion of the EMEAs internal scientific evaluation, the opinion of the EMEAs scientific committee is transmitted to the European Commission, the approval of which will form the basis of a single market authorization applying to the whole European Union.
The second procedure is mutual recognition which is mandatory for most conventional medicinal products. It is based upon the principle of mutual recognition of national authorizations and it provides for the extension of an MAA granted by one member state of the European Union to one or more other member states identified by the applicant. Should the original national authorization not be recognized in another member state, the points in dispute are submitted to EMEAs scientific committee for arbitration.
In both cases, the final decision is adopted by the European Commission, with the assistance of the EMEA or, in the event of serious disagreement between the member states, by the European Council. In addition, certain European countries outside the European Union follow the decisions of the European Commission.
In addition to the above forms of regulation, price constraints on pharmaceutical products exist in most countries either through governmental regulation or pressure from healthcare organizations. In some countries, governments or governmental agencies are substantial purchasers of human healthcare products and this also imposes an indirect form of regulation on the industry.
The Companys operations are subject to a number of environmental laws and regulations in each of the jurisdictions in which it operates governing, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater contamination, as well as employee health and safety.
The Companys Environmental Policy aims to foster a positive attitude towards the environment and to raise awareness of employees to responsible environmental practices at all sites operated by the Company. We ensure compliance with all relevant legislation and regulatory requirements and where practical and economically viable we develop standards in excess of such requirements.
Although the Company is only a small-scale manufacturer, it aims to set a high standard through continuous improvement in its environmental performance. The Company now undertakes routine monitoring of various measures of its environmental performance at its main research and development and manufacturing sites in Switzerland, France and the United States, the results of which are submitted to external review bodies.
45
The Company believes that its operations are currently in material compliance with all applicable environmental laws and regulations. In many jurisdictions, environmental requirements may be expected to become more stringent in the future, which could affect the Companys ability to obtain or maintain necessary authorizations and approvals and result in increased environmental compliance costs. While the Companys management does not believe that environmental compliance or remedial requirements are likely to have a material effect on the Company, there is no assurance that future material environmental compliance or remedial obligations will not arise in connection with the Companys operations or facilities or that such obligations will not have a material adverse effect on its business, financial condition or results of operations.
Property, Plants and Equipment
The Companys principal executive offices are located in an approximately 850 square meter (9,076 square feet) facility in London, England. The premises are occupied pursuant to a lease expiring in December 2015 with a rent review and break option in 2010. Annual rental fees will range from £281,000 to £421,500 during the period. The Company is currently in negotiations to sublease approximately half of this facility. The Company also leases office space in New York City, New York, which expires August 31, 2011. In August 2003, the Company took occupation of the entire building under an eight year tenancy agreement, at which time the annual rent was increased from $420,000 per annum to $720,000 per annum until August 2008, and $942,500 per annum from August 2008 to August 2011. A portion of these premises is currently sub-let by the Group. The Company is currently seeking to negotiate the termination of its New York premises lease.
In Lyon, France, the Company occupies a 17,000 square meter (183,000 square feet) pharmaceutical manufacturing and production facility and an approximately 2,400 square meter (25,850 square feet) adjoining office complex.
In addition, the Company owns a 4,400 square meter (47,363 square feet) facility in Muttenz, Switzerland in which its principal research and development, production, small-scale manufacturing, laboratory and workshop operations are housed. In February 1999, the Company purchased a warehousing and administration facility in Muttenz, Switzerland of approximately 7,300 square meters (78,579 square feet), including approximately 2,770 square meters (29,817 square feet) previously occupied by the Company under a leasing agreement. The building, which was extended and refitted to house additional administrative, research and laboratory operations, was officially re-opened on April 7, 2001.
SkyePharma Inc. maintains its principal operations in two leased buildings in San Diego, California. Its principal building is an approximately 7,600 square meter (82,000 square feet) facility housing production, administrative and research and development activities. This facility complies with cGMP regulations and is approved for the commercial manufacture of DepoDur. Clinical trial materials are also manufactured in this facility. The future minimum annual rental commitment for this facility will range from $3.2 million to $4.3 million per year over the balance of the remaining lease term of approximately 10 years based upon pre-established annual rent increases.
The second building is an approximately 2,020 square meter (21,746 square feet) facility built for the manufacture of DepoCyt®. This facility complies with cGMP regulations and is approved for commercial drug manufacturing by the FDA and EMEA. The lease on this facility expires in July 2015 and annual rental fees will range from $685,000 to $868,000 in this period.
Additionally, SkyePharma Inc. maintains a third leased facility in San Diego, California, with 427 square meter (4,576 square feet) of primarily warehouse space and an annualized rental cost of $52,000. The lease for this property expires in July 2006.
46
The Company expects that its obligations in respect of the SkyePharma Inc facilities will be transferred if the Injectables business is divested.
SkyePharma Canada maintained its principal operations in a leased 3,340 square meter (36,000 square feet) building located in Montreal, Quebec, Canada During 2003, the Company substantially reduced the staff of SkyePharma Canada and outsourced its activities to other SkyePharma sites. In August 2003, the Company amended its lease agreement to extend the lease term to expire December 31, 2013. Concurrently, the Company entered into a sublease with a third party for the facility expiring in December 31, 2013. During 2005 the sublessee went into liquidation. In January 2006 the Company entered into a new sublease with a new tenant (sublessee). In May 2006 the Company and the landlord terminated their lease agreement by the Company assigning its new sublease directly to the landlord. The Company has no further obligations for the facility in Canada.
During 2004, the Company completed the transfer of the activities of SkyePharma AB to other SkyePharma sites. The lease on SkyePharma ABs facility in Malmo, Sweden expired in November 2004 and was not renewed. Until June 2005 the Company rented temporary office space . The Company no longer maintains an office in Sweden.
The Company believes that its current facilities are adequate to meet its anticipated needs for the foreseeable future. For further discussion of the Companys manufacturing properties, see Business OperationsManufacturing above.
SkyePharma PLC is an international pharmaceutical company and has a number of wholly- owned subsidiaries.
Company |
|
|
|
Country of |
|
% Held(1) |
|
||
SkyePharma Canada Inc.* |
|
Canada |
|
|
100 |
% |
|
||
SkyePharma Production SAS* |
|
France |
|
|
100 |
% |
|
||
Krypton Limited |
|
Gibraltar |
|
|
100 |
% |
|
||
SkyePharma Holding AG* |
|
Switzerland |
|
|
100 |
% |
|
||
Jago Holding AG |
|
Switzerland |
|
|
100 |
% |
|
||
SkyePharma AG |
|
Switzerland |
|
|
100 |
% |
|
||
Jagotec AG |
|
Switzerland |
|
|
100 |
% |
|
||
SkyePharma Holding Inc.* |
|
U.S. |
|
|
100 |
% |
|
||
SkyePharma US Inc |
|
U.S. |
|
|
100 |
% |
|
||
SkyePharma Inc. |
|
U.S. |
|
|
100 |
% |
|
||
SkyePharma AB* |
|
Sweden |
|
|
100 |
% |
|
||
SkyePharma (Jersey) Ltd* |
|
Jersey |
|
|
100 |
% |
|
* Directly held by SkyePharma PLC.
(1) Portion of ownership interest equals portion of voting power held.
Item 4A: Unresolved Staff Comments
None
47
Item 5: Operating and Financial Review and Prospects
The following is a discussion of the results of operations and financial condition of SkyePharma PLC. You should read the following discussion, together with the whole of this Annual Report, including the historical consolidated financial statements and the related Notes included elsewhere in this Annual Report. The historical consolidated financial information for the years ended December 31, 2004 and 2005 included herein have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union (IFRS), with a reconciliation of significant differences between IFRS and U.S. GAAP. Prior to 2005, the Company prepared its annual consolidated financial statements under U.K. Generally Accepted Accounting Principles (U.K. GAAP). For the year ended December 31, 2005, the Company has prepared its annual consolidated financial statements in accordance with International Financial Reporting Standards and International Financial Reporting Interpretations Committee (IFRIC) interpretations as adopted by the European Union (EU) applicable to companies reporting under IFRS. There are no material differences for the Company between IFRS and IFRS as adopted by the EU. The 2004 comparatives have been restated as part of the first-time adoption requirements of IFRS. As allowed by SEC rules in relation to first-time adoption of IFRS, only one year of comparatives is reported in this Annual Report. IFRS differs in certain respects from accounting principles generally accepted in the United States (U.S. GAAP). The material differences between IFRS and U.S. GAAP relevant to the Company are explained in Note 37 to the consolidated financial statements of SkyePharma PLC included elsewhere in this Annual Report.
IFRS 1; First-Time Adoption of International Financial Reporting Standards (IFRS 1), sets out the transition rules which must be applied when IFRS is adopted for the first time. As a result, certain of the requirements and options in IFRS 1 may result in a different application of accounting policies in the 2004 restated information from that which would apply if the 2004 financial statements were prepared using full retrospective adoption of IFRS. The standard sets out certain mandatory exceptions to retrospective application and certain optional exemptions. Detailed disclosure on the mandatory exemptions applicable to SkyePharma and the optional exemptions taken are provided within Note 1 to the consolidated financial statements.
The reconciliation of the Companys net income for the two years ended December 31, 2005 primarily reflects differences in the accounting principles under IFRS and U.S. GAAP with respect to investments in associates, convertible bonds, Paul Capital funding liabilities and revenue recognition.
The reconciliations of the Companys shareholders funds as of December 31, 2005 and 2004, as restated, primarily reflect differences in the accounting principles under IFRS and U.S. GAAP in respect of business combinations, shares issued relating to contingent consideration, deferred shares to be issued, investments in associates, convertible bonds, Paul Capital funding liabilities and revenue recognition.
In connection with the preparation of the Companys Annual Report on Form 20-F, we detected an error in respect of goodwill in our reconciliations to U.S. GAAP in our 2004 financial statements. This restatement reduced the Companys shareholders funds under U.S. GAAP but did not affect our net loss under U.S. GAAP or financial statements under IFRS. Prior to the introduction of IFRS, under U.K. GAAP, in a purchase business combination amounts recorded in excess of assets acquired and liabilities assumed were recorded as goodwill in the accounts of the acquiring entity. Upon consolidation of the newly acquired subsidiary there was no need to translate the goodwill from the subsidiary currency to the reporting entity currency. Under U.S. GAAP this goodwill is recorded as an asset acquired in the purchased entity and the goodwill is recorded in the newly acquired entity. Upon consolidation of the acquired entity all assets and liabilities of the subsidiary, including the goodwill amounts, are required to be translated at the balance sheet date. In prior years we had made no adjustment for this difference in accounting treatment between U.K. GAAP and U.S. GAAP in our U.S. GAAP reconciliation. Consequently, we have restated our net assets and shareholders funds under U.S. GAAP at
48
December, 2004 to reflect the impact of the adjustments made to the Companys goodwill. As a result, the Companys restated U.S. GAAP shareholders funds reflect a decrease in net assets of £25.8 million in 2004 (from £84.7 million to £58.9 million). Further information is provided in Item 15: Controls and Procedures and Note 37 to our consolidated financial statements beginning on page F-1 of this Annual Report.
The Company has prepared its audited consolidated financial statements assuming that it will continue as a going concern. However, the Companys independent auditors, PricewaterhouseCoopers LLP, have included an emphasis of matter paragraph related to going concern in their auditors report, which refers to Note 1 to our consolidated financial statements beginning on page F-1 to the Annual Report stating that there is uncertainty as to when certain strategic initiatives may be concluded impacting the Groups working capital requirements. The audit opinion has not been qualified in this respect. The Companys audited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. See Report of Independent Registered Public Accounting Firm and Note 1 (a) to our consolidated financial statements beginning on page F-1 of this Annual Report.
The Companys strategy is to become a leading specialty pharmaceutical company powered through excellence in drug delivery. It uses multiple technologies to build a product pipeline for commercialization through out-licensing to co-development and marketing partners. The Company continually strives to acquire and develop new technologies and products to grow its position in the oral and inhalation drug delivery areas. The Company ultimately plans to selectively market its own products in targeted therapeutic areas.
The following table indicates the development of the Companys business over the course of the two years ended December 31, 2005 in terms of turnover and losses:
|
|
Year Ended |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Turnover |
|
75.2 |
|
61.3 |
|
Operating loss |
|
(3.1 |
) |
(37.5 |
) |
Net loss |
|
(18.6 |
) |
(50.9 |
) |
The Companys turnover principally comprises revenues from three sources:
· contract
development and licensing, including milestone payments and research and
development costs recharged (£27.6 million, 2005: £39.4 million, 2004);
· royalties receivable from sales by third parties of products developed by the Company (£21.7 million, 2005: £25.9 million, 2004); and
· manufacturing and distribution related revenue (£12.0 million, 2005: £9.9 million, 2004).
The Company is seeking to reduce its current dependence on milestone payments and increase the proportion of its revenues arising from royalties. The amount of milestone payments, if any, that the Company receives in any given period is influenced by a number of unpredictable factors, including scientific developments, the ability of the Company to find suitable partners, the timing of the negotiation and conclusion of agreements with such partners, the timing of regulatory approvals, the market introduction of new products and other factors.
Revenues for 2005, at £61.3 million, were 18% below the £75.2 million reported in 2004. This was primarily due to Paxil CR supply problems which the Company understands have subsequently been
49
resolved and slower overall market penetration of DepoDur by the marketing partner, partly offset by an increase in manufacturing and distribution revenues. In addition, the Company undertook a strategic shift away from license terms that prioritize upfront payments on signature towards deal structures with higher royalty rates and increased milestone payments tied to product revenue targets. Further, the Company did not license Flutiform during 2005. Excluding impairments of £19.4 million relating to the investments in Astralis, Vital Living and Micap and abortive transaction costs of £2.0 million, the operating loss increased by £34.4 million to £37.5 million, mainly due to the fall in revenue. The retained loss after the impairments and abortive transaction costs described above increased by £32.3 million to £50.9 million, mainly due to the higher one off charges and fall in revenue. Under U.S. GAAP the company recorded a net loss of £49.2 million, compared with a net loss of £20.8 million in 2004.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of the Consolidated Financial Statements requires the Company to make estimates and judgements that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company bases its estimates and judgements on historical experience and on various other assumptions that it considers to be reasonable. Actual results may differ from these estimates under different assumptions or conditions.
The Companys revenue comprises revenues from contract development and licensing, royalties and manufacturing and distribution. The Company enters a wide variety of collaborative arrangements with its partners from which it may earn all, or some of, these revenue streams. The application of the Companys revenue recognition policy to its complex collaboration agreements requires significant estimates and judgement. In particular, in arrangements with multiple deliverables, there may be significant judgement in separating the different revenue generating activities.
Paul Capital funding liabilities
The proceeds received from Paul Capital are treated as a liability under IAS 39 and are recorded within borrowings at the net present value of royalties expected to be paid to Paul Capital at the effective interest rate at inception of the agreement. Therefore, in order to be able to record the funding liability significant estimation of certain of the Companys future cash flows is required. Royalty cash flows are periodically reassessed to determine the estimated funding liability. In addition such flows are subject to foreign exchange movements.
Under the Companys accounting policies tests are performed annually to determine whether goodwill has suffered any impairment. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of estimates.
Impairment of other intangible assets and property, plant and equipment
Under the Companys accounting policies tests are performed annually to determine whether other intangible assets and property, plant and equipment have suffered any impairment. These calculations require the use of estimates.
Provisions for deferred consideration payable by the Company comprise the fair value of contingent consideration arising from acquisitions. The eventual outcome is subject to the Companys future
50
performance and certain contractual terms. Provisions are reviewed annually by the Directors, who make significant judgments as to the estimated fair value of the contingent consideration. Based on these judgments, changes to the estimated fair value of the consideration are recorded.
Provisions for contingent liabilities are dependent upon estimates and assessments of whether the criteria for recognition have been met, including estimates by the Directors as to the probable outcome and the amount of the potential cost of resolution. Any estimate for such an accrual would be developed in consultation with external legal advisors handling the Companys defense in these matters and would be based upon an analysis of potential outcomes.
The Company recognizes actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions directly in equity, in the period they have occurred, in accordance to the alternative treatment allowed by the amendment to IAS 19; Employee BenefitsActuarial Gains and Losses, Group Plans and Disclosures. The costs are assessed in accordance with advice received from independent actuaries. These assumptions include inflation rate, rate of increase in salaries, discount rate and expected return on plan assets and are disclosed in Note 26; Retirement benefit obligations to the Companys Consolidated Financial Statements. The selection of different assumptions could affect the future results of the Company.
Incentives in the form of shares are provided to employees under share option, share purchase and long term incentive plans. The fair value of the employee services received in exchange for the grant of the options and rewards is recognized as an expense. The expense is based upon a number of assumptions. The selection of different assumptions could affect the future results of the Company.
Other intangible assets are recorded at their fair value at acquisition date and are amortized on a straight line basis over their estimated useful economic lives from the time they are available for use. Any change in the estimated useful economic lives could affect the future results of the Company.
Current tax is the expected tax payable on the taxable income for the year using the tax rates and laws that have been enacted or substantially enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years. The Group has open tax issues with a number of revenue authorities and, on the basis of external professional advice, continues to believe that it has made adequate provision for any liabilities that may arise from these open assessments. The ultimate liability for such matters may vary from the amounts provided, and is dependent upon negotiations with the relevant tax authorities.
51
The following table sets forth selected items of the Companys consolidated income statement:
|
|
Year Ended |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Turnover |
|
75.2 |
|
61.3 |
|
Operating loss |
|
(3.1 |
) |
(37.5 |
) |
Net loss |
|
(18.6 |
) |
(50.9 |
) |
The Directors have determined that the Groups primary reporting format is by business segment with geographical reporting being the secondary format, based on the risks and returns of the various segments. SkyePharma is a speciality pharmaceutical Group, using its multiple drug delivery technologies to create a product pipeline for out-licensing to marketing partners. The business segments consist of the Oral, Inhalation and other business and the Injectable business. The geographic segments of U.K., Europe, North America and Rest of the World reflect the Groups most significant regional markets.
The Companys revenues are principally generated from three sources:
· contract
development and licensing, including milestone payments and research and
development costs recharged;
· royalties receivable from sales by third parties of products developed by the Company; and
· manufacturing and distribution related revenue.
Historically, the revenue contribution of each of the Companys revenue sources has varied from period to period. This is especially true of contract development and licensing revenues, the level of which may fluctuate, depending on a number of unpredictable factors, including scientific developments, the ability of the Company to find suitable partners, the timing of the negotiation and conclusion of agreements with such partners, the timing of regulatory approvals, the market introduction of new products and other factors. As a result, year-to-year comparisons of the Companys revenues may be materially distorted. See Item 3: Key InformationRisk FactorsThe Companys results of operations tend to fluctuate for more information on factors influencing the level of the Companys revenues.
Each of the Companys revenue sources yields significantly different gross margins. Accordingly, the comparability of gross margins from period to period is materially affected by the revenue mix in each period. For example, royalty revenues generally result in higher gross margins than contract development and licensing revenues. The Company pursues different strategies with respect to its various revenue sources. In respect of contract development and licensing revenue, the Company generally endeavors to recover its direct costs, its objective being to generate long-term profits from royalties on successful product commercializations.
After cost of sales, the Companys costs principally comprise research and development expenses, administration expenses, selling and marketing expenses, the costs of the corporate offices and interest expense. As the majority of the Companys expenses are incurred in Switzerland, France and the United States, whereas the Companys revenues are substantially denominated in U.S. dollars, the Companys results of operations, as reported in pounds sterling, may be materially influenced by exchange rate movements. To minimize the impact of any fluctuations, the Companys policy has historically been to maintain natural hedges. Where it has not been possible to use natural hedges, currency options, accrual
52
forward options and currency contracts are used. Foreign currency movements did not have a material impact on the results of operations in 2005 compared with 2004.
Inflation did not have a significant impact on the Companys operations during any of the periods presented below.
The Company is not aware of any other economic or political policies that could materially affect the Companys operations.
Year Ended December 31, 2005 compared with the Year Ended December 31, 2004
The following table sets forth selected items of our consolidated income statement for the two years ended December 31, 2005.
|
|
Year to |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Consolidated Income Statement |
|
|
|
|
|
Revenue |
|
75.2 |
|
61.3 |
|
Cost of sales |
|
(28.2 |
) |
(29.2 |
) |
Gross profit |
|
47.0 |
|
32.1 |
|
Selling, marketing and distribution expenses |
|
(1.7 |
) |
(5.9 |
) |
Administration expenses |
|
|
|
|
|
Amortization of other intangibles |
|
(2.2 |
) |
(2.1 |
) |
Other administration expenses |
|
(20.3 |
) |
(35.2 |
) |
|
|
(22.5 |
) |
(37.3 |
) |
Research and development expenses |
|
(28.0 |
) |
(26.0 |
) |
Other income/(expense) |
|
2.1 |
|
(0.4 |
) |
Operating loss |
|
(3.1 |
) |
(37.5 |
) |
Finance costs |
|
(23.9 |
) |
(22.3 |
) |
Finance income |
|
8.6 |
|
10.0 |
|
Share of loss in associate |
|
|
|
(0.8 |
) |
Loss before income tax |
|
(18.4 |
) |
(50.6 |
) |
Income tax expense |
|
(0.2 |
) |
(0.3 |
) |
Loss for the year |
|
(18.6 |
) |
(50.9 |
) |
The following table breaks down the Companys turnover by revenue category for the two years ended December 31, 2004 and 2005:
|
|
Year Ended |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Contract development and licensing |
|
39.4 |
|
27.6 |
|
Royalties |
|
25.9 |
|
21.7 |
|
Manufacturing and distribution |
|
9.9 |
|
12.0 |
|
Total |
|
75.2 |
|
61.3 |
|
The Groups revenues continue to be sensitive to the timing and receipt of milestone payments and payments received on the signing of new contracts. Revenues for 2005, at £61.3 million, were 18% below the £75.2 million reported in 2004. This was primarily due to Paxil CR supply problems which the
53
Company understands have subsequently been resolved and slower overall market penetration of DepoDur by the marketing partner, partly offset by an increase in manufacturing and distribution revenues. In addition, the Company undertook a strategic shift away from license terms that prioritize upfront payments on signature towards deal structures with higher royalty rates and increased milestone payments tied to product revenue targets. Further, the Company did not licence Flutiform during 2005.
Contract Development and Licensing
The following table breaks down the Companys contract development and licensing revenues for the two years ended December 31, 2004 and 2005:
|
|
Year Ended |
|
||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Milestone payments |
|
33.4 |
|
22.1 |
|
Research and development costs recharged |
|
6.0 |
|
5.5 |
|
|
|
39.4 |
|
27.6 |
|
Total contract development and licensing revenue decreased 30% to £27.6 million, compared with £39.4 million in 2004. This was primarily due to the change in the structure of our license agreements described above. Revenues recognized from milestone payments and payments received on the signing of agreements amounted to £22.1 million in 2005 compared with £33.4 million in 2004. The 2005 total included revenues from Sciele Pharma for the U.S. marketing and distribution rights for Triglide® triggered by FDA approval in May 2005, from Mundipharma for the licensing of DepoBupivacaine for Europe and from Maruho for the licensing of DepoBupivacaine for Japan. In addition, £5.7 million of revenue was recognized from GlaxoSmithKline on the phase III clinical trials of Requip® (ropinirole), from AstraZeneca on the phase III clinical trials of Pulmicort® HFA-MDI and from Novartis on the phase II clinical trials of QAB 149. Research and development costs recharged fell by 8% to £5.5 million, compared with £6.0 million in 2004. This was mainly due to a fall in the costs recharged to Micap plc in respect of the development of their microencapsulation technology, which has now been completed.
Royalties
Royalty income decreased by 16% to £21.7 million, compared with £25.9 million in 2004. Royalty income in 2005 was derived principally from Paxil CR, Xatral® OD, DepoCyt®, Solaraze®, DepoDur and Triglide®. Although the Company was able to negotiate an increase in the royalty rate it receives on GlaxoSmithKlines sales of Paxil CR from 3% to 4% with effect from March 2005 and also received royalties based on budgeted sales while the product was temporarily off the U.S. market, royalties were still negatively impacted by the continuing supply problems experienced by GlaxoSmithKline. Excluding Paxil CR, royalties for SkyePharmas other products grew by 38%. In addition, royalty growth was less than anticipated due to slower overall market penetration of Triglide® and DepoDur by marketing partners during the year.
Manufacturing and Distribution
Manufacturing and distribution revenue increased by 21% to £12.0 million, compared with £9.9 million in 2004, mainly due to higher production of clinical trial material and launch quantities for Novartis in respect of QAB 149 and Foradil® Certihaler.
54
Deferred income
During 2005, there was a net reduction in deferred income of £3.5 million under SkyePharmas revenue recognition policy. The movement in deferred income was:
|
|
December 31, |
|
Received* |
|
Recognized |
|
December 31, |
|
||||||||
|
|
(in £ millions) |
|
||||||||||||||
Contract development and licensing revenue |
|
|
14.1 |
|
|
|
24.1 |
|
|
|
(27.6 |
) |
|
|
10.6 |
|
|
* Includes exchange adjustments.
Expenses
Cost of sales comprises research and development expenditures, including:
· the costs of certain clinical trials incurred on behalf of the Companys collaborative partners,
· the direct costs of contract manufacturing,
· the direct costs of licensing arrangements, and
· royalties payable.
Cost of sales increased by 4% to £29.2 million in 2005, compared with £28.2 million in 2004. This was mainly due to an increase in manufacturing and distribution expenses ahead of the approval and launch of Triglide®.
The resulting gross profit decreased 32% to £32.1 million, compared with £47.0 million in 2004.
Selling, Marketing and Distribution Expenses
Selling, marketing and distribution expenses increased significantly to £5.9 million, compared with £1.7 million in 2004. This mainly reflected SkyePharmas contribution towards the initial launch and marketing costs of DepoDur and Triglide®. No further marketing contributions are due in respect of DepoDur and contributions on Triglide® will terminate in 2007. The Companys total costs in respect of Triglide® in 2005 amounted to approximately £4.6 million.
Amortization of other intangibles
Amortization of intangible assets decreased slightly to £2.1 million, compared with £2.2 million in 2004.
Other Administration Expenses
Excluding the impairments of £19.4 million and abortive transactions costs of £2.0 million described below, other administration expenses were £13.8 million in 2005, 12% lower than the £15.6 million reported in 2004, this reflects the first full year of cost savings following the restructuring started in 2004. Following the Strategic Review and the Groups decision to focus on its core oral and pulmonary products and to divest its injectable business, the Group no longer views its collaborations with Astralis, Vital Living and Micap as strategic and these investments have therefore been impaired. In addition, as an injectable project, SkyePharmas entitlement to negotiate for commercial rights for Psoraxine, Astralis key product, is being offered with the injectable business interests. The remaining £2.0 million of the one off charge relates to legal and professional fees relating to an aborted transaction. Other administration expenses including impairments and abortive transaction costs increased by £14.9 million to £35.2 million.
55
Research and Development Expenses
SkyePharmas own research and development expenses in the year decreased by £2.0 million from £28.0 million in 2004 to £26.0 million in 2005, mainly due to a reduction in expenditure on Pulmicort® HFA-MDI, DepoDur and other injectable products, partly off set by an increase in expenditure on Flutiform and DepoBupivacaine in advance of their commencement of phase III clinical trials.
Other income/(expense)
The other expense of £0.4 million comprises a £0.7 million loss due to the movement in the fair value of the Groups investment in GeneMedix plc, partly off set by a £0.3 million profit on disposal of part of the Groups holding of Vectura Group plc shares.
Results
Excluding the impairments of £19.4 million and abortive transaction costs of £2.0 million described above, the operating loss was £16.1 million in 2005, compared with £0.4 million in 2004, due principally to the reduction in revenue and to increased marketing contributions. The operating loss after impairments and abortive transaction costs increased by £34.4 million to £37.5 million, mainly due to the higher one off charges and fall in revenue.
The finance costs of £22.3 million (2004: £23.9 million) mainly comprise interest on the Paul Capital funding liabilities as well as interest on the convertible bonds. Finance income includes £9.0 million (2004: £6.0 million) in respect of a change in the estimated future payments to Paul Capital.
The Groups share of the losses of Astralis was £0.8 million for 2005, compared with £10,000 in 2004.
The retained loss after impairments and abortive transaction costs increased by £32.3 million to £50.9 million, also due to the higher one off charges and fall in revenue.
The loss per share after impairments and abortive transaction costs was 8.1 pence, which compares with 3.0 pence in 2004.
Foreign currency movements did not have a material impact on the results of operations in 2005 compared with 2004.
56
Earnings before interest, tax, depreciation amortization and impairments showed a loss of £10.6 million in 2005, compared with a profit of £8.6 million in 2004. Management believes that earnings before interest, tax, depreciation amortization and impairments provides useful information to investors because it provides a clearer picture of the Companys operating performance by excluding items relating to the Companys financing and investing activities.
|
Year ended |
|
|||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Reconciliation of loss for the year to earnings before interest, tax, depreciation amortization and impairments |
|
|
|
|
|
Loss for the year |
|
(18.6 |
) |
(50.9 |
) |
Finance costs |
|
23.9 |
|
22.3 |
|
Finance income |
|
(8.6 |
) |
(10.0 |
) |
Income tax expenses |
|
0.2 |
|
0.3 |
|
Depreciation |
|
6.0 |
|
6.2 |
|
Amortization |
|
2.2 |
|
2.1 |
|
Impairments |
|
3.5 |
|
19.4 |
|
Earnings before interest, tax depreciation, amortization and impairments |
|
8.6 |
|
(10.6 |
) |
Segment information
Segmental information on revenue, operating loss excluding the impairments and abortive transaction costs described above, and assets and liabilities is as follows:
|
Year ended |
|
|||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Revenue |
|
|
|
0 |
|
Injectable |
|
25.6 |
|
10.5 |
|
Oral, Inhalation and other |
|
49.6 |
|
50.8 |
|
|
|
75.2 |
|
61.3 |
|
Operating loss excluding the impairments and abortive transaction costs described above |
|
|
|
|
|
Injectable |
|
(1.4 |
) |
(18.6 |
) |
Oral, Inhalation and other |
|
1.0 |
|
2.5 |
|
|
|
(0.4 |
) |
(16.1 |
) |
Business segment data includes an allocation of corporate costs to each segment.
|
Year Ended |
|
|||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Assets |
|
|
|
|
|
Injectable |
|
60.4 |
|
57.1 |
|
Oral, Inhalation and other |
|
95.6 |
|
93.3 |
|
Total operating assets |
|
156.0 |
|
150.4 |
|
Liabilities |
|
|
|
|
|
Injectable |
|
(30.5 |
) |
(40.1 |
) |
Oral, Inhalation and other |
|
(54.0 |
) |
(41.4 |
) |
Total operating liabilities |
|
(84.5 |
) |
(81.5 |
) |
57
LIQUIDITY AND CAPITAL RESOURCES
The following is a summary of the Groups contractual cash obligations as of December 31, 2005:
|
|
|
Payments Due by Period |
|
|||||||||||||||
|
|
Total |
|
< 1 year |
|
1-3 years |
|
3-5 years |
|
After 5 years |
|
||||||||
|
|
(in £ millions) |
|
||||||||||||||||
Bank loans |
|
2.9 |
|
|
2.3 |
|
|
|
0.6 |
|
|
|
|
|
|
|
|
|
|
Property mortgage |
|
6.9 |
|
|
0.3 |
|
|
|
0.6 |
|
|
|
0.5 |
|
|
|
5.5 |
|
|
Finance lease liabilities |
|
0.1 |
|
|
0.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases |
|
27.3 |
|
|
2.3 |
|
|
|
5.0 |
|
|
|
5.4 |
|
|
|
14.6 |
|
|
Convertible bonds due May 2024 |
|
69.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69.6 |
|
|
Convertible bonds due June 2025 |
|
20.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.0 |
|
|
Paul Capital funding liabilities |
|
29.3 |
|
|
3.8 |
|
|
|
7.6 |
|
|
|
7.6 |
|
|
|
10.3 |
|
|
Provisions |
|
1.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.9 |
|
|
Total Contractual Cash Obligations |
|
158.0 |
|
|
8.8 |
|
|
|
13.8 |
|
|
|
13.5 |
|
|
|
121.9 |
|
|
Capital commitments, contracted for but not provided in the accounts, were £Nil at December 31, 2005 and £Nil million at December 31, 2004.
The Group does not have any off-balance sheet arrangements that have or are reasonably likely to have a material effect on the Groups financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Cash requirements
The Companys working capital requirements continue to be affected by the timing and receipt of milestone payments and payments received on the signing of new contracts. The Companys future cash flows will also be impacted by the Companys change in strategy, principally its stated aim of moving to sustainable profitability in the near term and its refocus to concentrate on oral and pulmonary products. Consequently the Companys near term working capital requirements are uncertain and sensitive to the timing of a number of initiatives required to provide the financial flexibility to implement the new strategy. The Companys independent auditors, PricewaterhouseCoopers LLP, have included an emphasis of matter paragraph related to going concern in their auditors report, which refers to Note 1 to our consolidated financial statements beginning on page F-1 to this Annual Report stating that there is uncertainty as to when certain strategic initiatives may be concluded and their effect on the Companys working capital requirements, which raises substantial doubt as to the Companys ability to continue as a going concern. The audit opinion has not been qualified in this respect. The Companys initiatives to improve profitability and the Companys working capital requirements include the licensing of Flutiform in Europe, the divestment of its injectable business interests, which is expected to require shareholder approval, or the U.S. licensing for DepoBupivacaine. The investment bank UBS bas been retained to manage the sale of the injectables business. Following a marketing exercise several expressions of interest have been received, due diligence materials have been prepared and management presentations are being made to interested parties. Management are currently evaluating the expressions of interest and interested parties have been and are continuing to undertake due diligence. For further information on the Companys new strategy see Item 4: Information on the CompanyBusiness OperationsStrategy.
The Directors have reviewed the working capital requirements of the Company for the next twelve months and have a reasonable expectation that sufficient funds will be raised from these initiatives and that the Company will continue in operational existence for the foreseeable future. There can be no assurance that additional funds will be available on a timely basis, on favorable terms or at all, or that such funds, if raised, would be sufficient to permit the Company to continue to conduct its operations. If
58
adequate funds are not available, the Company may be required to curtail significantly, or discontinue, one or more of its research and development programs.
The Company is an emerging pharmaceutical company and expects to continue to absorb cash until products are fully commercialized. Much of the Companys cash requirements are of an investment nature and are to a great extent discretionary. Funds will be used for the Companys own product development efforts and capital expenditure. Capital commitments as at December 31, 2005, amounted to £Nil (2004: £Nil).
If the Companys currently available funds and internally generated cash flow are not sufficient to satisfy its financing needs, the Company will be required to seek additional funding through other arrangements with corporate collaborators, through bank borrowings, through public or private sales of its securities, including equity securities. Any such collaboration could result in limitations on the resources the Company could devote to research, development and commercialization of new products and product candidates, if any, as well as its profits therefrom. In addition, the terms of any future bank borrowings could place restrictions on the Companys ability to take certain actions, and any equity financing could result in dilution to the Companys shareholders. The Company does not currently have any committed sources of additional capital.
Future acquisitions or investments, a material decrease in our cash flow from operations or the failure of our collaborative partners to provide funding are factors which could affect our liquidity and working capital. The Company is reliant on collaborative partners and upon its ability to continue to obtain new development contracts from third parties to further develop and commercialize its drug delivery technologies. See Item 3: Key InformationRisk Factors. The Company is dependent on its Geomatrix technology as to which further successful development is uncertain and any failure by the Companys collaborative partners to provide funding, obtain regulatory approvals and conduct marketing activities could adversely affect the Companys business, results, financial condition and liquidity.
Sources and uses of cash
|
Year ended |
|
|||
|
|
2004 |
|
2005 |
|
|
|
(in £ millions) |
|
||
Net cash used in operating activities |
|
(3.9 |
) |
(7.9 |
) |
Net cash used in investing activities |
|
(5.3 |
) |
(3.9 |
) |
Net cash generated from financing activities |
|
2.9 |
|
30.6 |
|
Effect of exchange rate changes |
|
(0.4 |
) |
0.2 |
|
Net (decrease)/increase in cash and cash equivalents |
|
(6.7 |
) |
19.0 |
|
Cash and cash equivalents at beginning of the year |
|
22.0 |
|
15.3 |
|
Cash and cash equivalents at end of the year |
|
15.3 |
|
34.3 |
|
The Company finances its operations primarily by cash generated from the sale of equity and debt securities and funding provided by collaborative partners and operations.
As discussed above, a significant proportion of the Companys cash resources comprise milestone payments under licensing and marketing agreements between the Company and its collaborative partners. The amount of milestone payments that the Company receives in any given period is influenced by a number of unpredictable factors, including scientific developments, the ability of the Company to find suitable partners, the timing of the negotiation and conclusion of agreements with such partners, the timing of regulatory approvals, the market introduction of new products and other factors. Although the Company is seeking to decrease the proportion of its revenues derived from milestone payments, the
59
uncertainty associated with milestone payments means that there is no assurance that the Company will be able to obtain sufficient funds to satisfy its financing needs.
Net cash used in operating activities
During 2005 there was a net cash outflow from operating activities after tax of £7.9 million, compared with £3.9 million in 2004. The Group paid £2.0 million of costs relating to an aborted strategic transaction during the year.
Net cash used in investing activities
During the year the Group spent £2.6 million on property, plant and equipment and expenditure on intangible assets of £2.3 million mainly relates to the purchase of licenses to intellectual property in the area of pulmonary delivery. The proceeds on disposal of the Groups non strategic holding of Vectura shares were £1.6 million.
Net cash generated from financing activities
Cash inflows from financing in 2005 were £30.6 million (2004: £2.9 million). The Group raised £34.8 million net of expenses by means of a rights issue of 125,627,357 new Ordinary Shares. During the year the Group issued £20.0 million 8% convertible bonds raising £18.8 million net of expenses. In addition the company repaid the £9.8 million balance on the convertible bonds due June 2005. Borrowings of £7.4 million were repaid in the period (2004: £8.6 million). This primarily comprises Paul Capitals share of the Companys royalty income.
Debt instruments, guarantees and related covenants
Bank and other non convertible debt amounted to £9.9 million at December 31, 2005 (2004: £11.1 million), consisting principally of a £6.9 million property mortgage secured on the assets of Jago (2004: £7.4 million). In addition, the Company has 6% convertible bonds due May 2024 of £69.6 million (2004: £69.6 million) and 8% convertible bonds due June 2025 of £20.0 million (2004: £Nil). Net debt (excluding the Paul Capital funding liabilities) amounted to £39.2 million (2004: £55.6 million).
Bank borrowings
At December 31, 2005 bank borrowings include two amounts due to the Basellandschaftliche Kantonalbank of £0.9 million (CHF 2 million) and £0.7 million (CHF 1.5 million) (2004: £0.9 million (CHF 2 million) and £0.7 million (CHF 1.5 million)). Both loans can be terminated with six weeks notice by either party and bear interest at 6.5% and 6.0% respectively. Both loans are secured on the assets of Jago and the £0.7 million (CHF 1.5 million) loan is guaranteed by SkyePharma PLC.
The Group had a loan as at December 31, 2005 with GE Capital Corp of £1.4 million ($2.4 million) (2004: £1.9 million ($3.7 million)). The loan is secured by certain assets of SkyePharma Inc, SkyePharma U.S. Inc and SkyePharma PLC. The loan bears interest at 8.0% and is repayable by instalments until September 2007.
Convertible bonds
In June 2005, the Group issued £20.0 million 8% convertible bonds, with a first put after five years by the holder of the bonds, and a final maturity of June 2025. The bonds are convertible at the option of the holder into Ordinary Shares in the Company at an initial conversion price of 77 pence at any time prior to maturity. The bond contains a price reset feature such that if on June 3, 2006 the Companys average share price for the preceding 10 days (reset price) is less than the conversion price, then the conversion price
60
shall be adjusted to the reset price subject to a maximum reduction of 25% in the conversion price. The conversion price was reset to 58 pence on June 3, 2006. Unless previously redeemed or converted, the bonds will be redeemed by the Group at their principal amount in June 2025. The convertible bonds existing at December 31, 2005, due in May 2024, were not affected by this transaction.
On June 19, 2005 £9.8 million of convertible bonds due June 2005 were redeemed in full by the Company at their principal amount.
As a result of these transactions the Company has £69.6 million convertible bonds due May 2024 at a conversion price of 95 pence, and £20.0 million convertible bonds due June 2025 at a conversion price of 58 pence.
Property mortgage
At December 31, 2005, the Group had a property mortgage facility with the Basellandschaftliche Kantonalbank of £6.9 million (CHF 15.5 million) (2004: £7.4 million (CHF 16.1 million)). The mortgage is in two tranches, both secured by the assets of Jago. The first tranche of £2.7 million (CHF 6.2 million) bears interest at 2.75% and is repayable by instalments over 20 years semi-annually. The second tranche of £4.1 million (CHF 9.3 million) bears interest at 2.75% and is repayable by instalments over 50 years semi-annually.
Paul Capital funding liabilities
The Group entered into two transactions with Paul Capital in 2000 and 2002. Under these transactions Paul Capital provided a total of $60 million in return for the sale of a portion of the potential future royalty and revenue streams on a selection of the Groups products.
Whilst the contractual arrangement with Paul Capital is a royalty agreement under which royalties are payable on revenues earned and payments received, the proceeds received from Paul Capital meet the definition of a financial liability under IAS 32, and are treated as a financial liability. Royalties paid to Paul Capital are treated as repayment of the liability and interest is charged on the liability using the effective interest rate at inception of each agreement. The estimated future payments to Paul Capital are discounted using each contracts original effective interest and any adjustment is recognized as income or expense in the income statement.
Finance lease liabilities
Obligations under hire purchase and finance leases are secured upon the assets to which they relate and as at December 31, 2005 £Nil (2004: £0.1 million (SKR 0.9 million)) is guaranteed by the Company.
Financial instruments
The Group holds financial instruments to finance its operations and to manage the currency risks that arise from these operations. Further information on these financial instruments is set out in Note 25 of the Notes to SkyePharmas Consolidated Financial Statements included in Item 17 of this Form 20-F.
PRINCIPAL DIFFERENCES BETWEEN IFRS AND U.S. GAAP
The Companys financial statements have been prepared in accordance with IFRS, which differs in certain respects from U.S. GAAP. Included in Item 17 of this Form 20-F is a reconciliation of the Companys net income for the years ended December 31, 2005 and 2004 and shareholders funds as of December 31, 2005 and 2004 from IFRS to U.S. GAAP.
61
The reconciliation of the Companys net income for the two years ended December 31, 2005 primarily reflects differences in the accounting principles under IFRS and U.S. GAAP with respect to investments in associates, revenue recognition and Paul Capital funding liabilities.
The reconciliations of the Companys shareholders funds as of December 31, 2005 and 2004 primarily reflect differences in the accounting principles under IFRS and U.S. GAAP in respect of business combinations, shares issued relating to contingent consideration, deferred shares to be issued, convertible bonds, Paul Capital funding liabilities and revenue recognition.
The financial information for the year ended December 31, 2005 has been prepared for the first time in accordance with IFRS. In preparing the financial information certain first-time adoption provisions have been applied. The Groups accounting policies and adjustments made on the implementation of IFRS were disclosed in the interim results announcement issued on September 28, 2005 and the IFRS restatement announcement issued on August 3, 2005 and can be found on the Groups corporate web site (www.skyepharma.com). Since the publication of these results the Group has changed its interpretation of the application of IAS 39 to the Paul Capital funding liabilities. The restatement resulted in a decrease in the 2004 net interest expense of £5.2 million and in the liability at December 31, 2004 of £4.3 million.
NEW ACCOUNTING STANDARDS NOT YET ADOPTED
SkyePharma has decided not to adopt early application of the following standards, amendments and interpretations (already adopted or in the process of being adopted by the European Union):
· IFRS 7; Financial InstrumentsDisclosures, which is applicable from January 1, 2007; and
· IAS 39; Cash Flow Hedge Accounting of Forecast Intragroup Transactions, applicable from January 1, 2006.
SkyePharma is currently analyzing the practical consequences of these new standards and interpretations and the impact of their application on its financial statements. The Group is not impacted by interpretations IFRIC 2; Members Shares in Co-operative Entities and Similar Instruments, IFRIC 5; Rights to Interests Arising from Decommissioning, Restoration and Environmental Funds, IFRIC 6; Liabilities Arising from Participating in a Specific MarketWaste Electrical and Electronic Equipment and IFRIC 7; Applying the Restatement Approach under IAS 29Financial Reporting in Hyperinflationary Economies,
In January 2006, the International Accounting Standards Board issued IFRIC 8; The Scope of IFRS 2 (IFRIC 8). IFRIC 8 clarifies that the accounting standard IFRS 2; Share based payment, applies to arrangements where an entity makes share-based payments for apparently nil or inadequate consideration. The interpretation explains that, if the identifiable consideration given appears to be less than the fair value of the equity instruments granted or liability incurred, this situation typically indicates that other consideration has been or will be received. IFRIC 8 is effective for SkyePharma for the period beginning January 1, 2007. SkyePharma is currently reviewing this issue to measure the potential impact on its consolidated results of operations, financial position, and cash flows.
62
IFRIC 9Reassessment of Embedded Derivatives
In March 2006, the International Accounting Standards Board issued IFRIC 9; Reassessment of Embedded Derivatives (IFRIC 9). IFRIC 9 concludes that an entity must assess whether an embedded derivative is required to be separated from the host contract and accounted for as a derivative when the entity first becomes a party to the contract. Subsequent reassessment is prohibited unless there is a change in the terms of the contract that significantly modifies the cash flows that otherwise would be required under the contract, in which case reassessment is required. IFRIC 9 is effective for SkyePharma for the period beginning January 1, 2007. SkyePharma is currently reviewing this issue to measure the potential impact on its consolidated results of operations, financial position, and cash flows.
SFAS 154; Accounting changes and Error Corrections, a replacement of APB Opinion No. 20 and FAS 3.
In June 2005, the Financial Accounting Standards Board issued SFAS 154; Accounting Changes and Error Corrections, a replacement of APB Opinion No. 20 and FAS 3 (SFAS 154). This statement replaces Opinion 20 and FAS 3, and changes the requirements for the accounting for, and reporting of, a change in accounting principle. APB Opinion No. 20 previously required that most voluntary changes in accounting principle be recognized by including in net income of the period of the change the cumulative effect of changing to the new accounting principle. SFAS 154 requires retrospective application to prior periods financial statements of changes in accounting principle. SFAS 154 is effective for SkyePharma for the period beginning January 1, 2006. SkyePharma is currently reviewing this issue to measure the potential impact on the consolidated results of operations, financial position, and cash flows.
FSP No. FAS 115-1 and FSP FAS 124-1; The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments.
In November 2005, the Financial Accounting Standards Board issued this FASB Staff Position (FSP) which addresses the determination as to when an investment is considered impaired, whether that impairment is other than temporary, and the measurement of an impairment loss. This FSP also includes accounting considerations subsequent to the recognition of an other-than-temporary impairment and requires certain disclosures about unrealized losses that have not been recognized as other-than-temporary impairments. The guidance in this FSP amends FASB Statements No. 115, Accounting for Certain Investments in Debt and Equity Securities, and No. 124, Accounting for Certain Investments Held by Not-for-Profit Organizations, and APB Opinion No. 18, The Equity Method of Accounting for Investments in Common Stock. FSP FAS 115-1 is effective for SkyePharma for the period beginning January 1, 2006. SkyePharma is currently reviewing this issue to measure the potential impact on the consolidated results of operations, financial position, and cash flows.
Other recent accounting pronouncements issued by the FASB (including the Emerging Issues Task Force), the AICPA, and the SEC are not believed by management to have a material impact on SkyePharmas present or future consolidated financial statements.
RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES
For a discussion of the Companys research and development activities, see Item 4: Information on the CompanyBusiness OperationsResearch and Development and information on patents and licenses, see Item 4: Information on the CompanyBusiness OperationsPatents and Proprietary Rights.
63
The Companys results of operations have fluctuated materially on a monthly, half yearly and yearly basis, partly as a result of acquisitions and partly due to the timing of contract development and licensing revenues. Therefore, period-to-period and period-on-period comparisons are not meaningful at this stage in the Companys development. The Company believes that it will continue to experience fluctuations in its results of operations in the near to medium term.
Item 6: Directors, Senior Management and Employees
Directors and Senior Management
Name |
|
|
|
Age |
|
Position |
Dr. Argeris (Jerry) Karabelas |
|
53 |
|
Non-Executive Chairman |
||
Frank Condella(1) |
|
52 |
|
Chief Executive Officer and Executive Director |
||
Donald Nicholson(1) |
|
48 |
|
Finance Director and Executive Director |
||
Dr. Kenneth Cunningham(1) |
|
53 |
|
Chief Operating Officer and Executive Director |
||
Dr. David Ebsworth(2)(3) (4) |
|
51 |
|
Non-Executive Director |
||
Alan J Bray(2)(4) |
|
62 |
|
Non-Executive Director |
||
R. Stephen Harris(3)(4) |
|
64 |
|
Non-Executive Director |
(1) Member of Executive Committee.
(2) Member of Audit Committee.
(3) Member of Remuneration Committee.
(4) Member of Nomination Committee.
The following information is provided as at June 23, 2006, the latest practicable date prior to the filing of this Report.
Dr. Argeris (Jerry) Karabelas became Non-Executive Chairman in February 2006, having been appointed to the Board in November 2000. Dr Karabelas has more than 23 years experience in the pharmaceutical industry, having spent the majority of his career with SmithKline Beecham. Dr Karabelas is a partner at Care Capital LLC. He was previously the CEO of Novartis Pharma AG where he had responsibility for pharmaceuticals, R&D, consumer products, and the generics business. He is also an external director of the International Partnership for Microbicides and chairman of Human Genome Sciences. He is also a director of NitroMed Inc., Acura Pharmaceuticals Inc., Inotek Pharmaceuticals Corporation, Anadys Pharmaceuticals Inc., Renovo PLC and a member of the scientific advisory board of Epigenesis Pharmaceuticals LLP and CardioKine Inc. He received a Ph.D in Pharmacokinetics from the Massachusetts College of Pharmacy in 1979.
Frank Condella became Chief Executive Officer in March 2006 and was appointed to the Board in April 2006. Mr Condella has over 25 years commercial experience in the pharmaceutical industry, having worked for several major international companies. Prior to joining SkyePharma he served as president of european operations for IVAX Corporation, CEO of Faulding Pharmaceuticals, vice-president of the Specialty Business for F. Hoffman-La Roche Ltd, and vice-president and general manager of Lederle Standard Products at American Home Products. He holds a BS in Pharmacy degree and an MBA from Northeastern University in Boston, Massachusetts.
Donald Nicholson was named Finance Director in March 1997. He joined the Company in February 1996 as Chief Financial Officer and was appointed to the Board in March 1997. He has over 20 years of experience in the healthcare industry including Wellcome plc and Corange Ltd, the holding company of Boehringer Mannheim and DePuy, where he was corporate strategy and finance director. He is a member of the Institute of Chartered Accountants of Scotland and obtained a B. Com (Hons) degree from the University of Edinburgh in 1980.
64
Dr. Ken Cunningham became Chief Operating Officer in April 2006 and was appointed to the Board in May 2006. Dr. Cunningham was formerly CEO of Arakis Ltd from January 2002 to August 2005, vice-president european affairs for Alza Corporation and vice-president clinical development for Sequus Pharmaceuticals. Previously he held a variety of clinical development and commercial strategy positions in GlaxoWellcome and Warner-Lambert. He is a non-executive director of Xention Discovery Ltd. Dr Cunningham qualified from St Marys Medical School, London University.
Alan Bray was appointed to the Board in September 2004. He is a chartered accountant, having retired as a senior partner from Deloitte & Touche LLPs financial services practice in May 2004. Mr Bray has worked with retail and investment banks, insurance companies and asset management firms and was seconded for a time to the Department of Trade and Industry. He was responsible for Deloitte & Touche LLPs risk management policies and procedures in its financial services practice and was a serving member on a DTI Supervisory Board and Audit Committee. Mr Bray is a Fellow of the Institute of Chartered Accountants in England and Wales.
Dr. David Ebsworth was appointed to the Board in April 2002. Dr. Ebsworth has over 25 years of pharmaceutical industry experience. He provides consultancy services to a variety of clients including venture capital companies. He was chief executive officer of Oxford GlycoSciences PLC until May 2003. Prior to this he held the position of president and general manager of the Pharmaceutical Business Group for Bayer AG in Leverkusen, Germany, and has also worked for Bayer AG in a series of global positions in Canada, Europe and the United States. Dr. Ebsworth is non-executive chairman of Wilex AG, Xention Discovery Ltd. and Curacyte AG and a non-executive director of Intercell AG, CuraGen Corporation and Renovo PLC and held the same office, until 1998, with Schein Pharmaceutical, Inc. (now known as Watson Pharmaceuticals, Inc). He obtained a B.Sc in Chemistry and German in 1976 and a Ph.D in Industrial Relations in 1980 from the University of Surrey.
R Stephen Harris was appointed to the Board in November 1995. He has 40 years of experience in the pharmaceutical industry, having worked for ICI Pharmaceuticals, Merck, Eli Lilly, Boots, Reckitt & Colman and Gensia; and was director of Development and Licensing with Medeva plc. He is non-executive chairman of Proteome Sciences plc, Sinclair Pharma plc and Conve PLC and non-executive director of Advanced Medical Solutions Group plc, Premier Research PLC and GeneMedix plc. He is a member of the Pharmaceutical Society of Great Britain and graduated with a B.Sc in Pharmacy from the University of London in 1964.
There are no other arrangements or understandings with major shareholders, customers or suppliers or others pursuant to which any person was selected to serve as a director or senior manager.
There are no provisions within the directors service contracts that provide for any benefit to accrue to any director upon termination of employment save that salary may be paid in lieu of notice.
65
In 2005, the Company paid £1,523,000 in aggregate to its Directors (10 persons).
The following table provides certain information regarding the compensation paid to Directors and Senior Management in 2005.
|
|
|
|
|
|
|
|
Pension Benefits |
|
All Other |
|
||||||||
|
|
(In £ thousands) |
|
||||||||||||||||
Ian Gowrie-Smith |
|
|
140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Michael Ashton(2) |
|
|
440 |
|
|
|
110 |
|
|
|
77 |
|
|
|
48 |
|
|
||
Donald Nicholson |
|
|
250 |
|
|
|
63 |
|
|
|
44 |
|
|
|
10 |
|
|
||
Air Chief Marshal Sir Michael Beavis |
|
|
58 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Alan Bray |
|
|
54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Dr. David Ebsworth |
|
|
53 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Stephen Harris |
|
|
51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Dr. Argeris (Jerry) Karabelas |
|
|
51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Dr. Keith Mansford |
|
|
49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Torao Yamamoto(3) |
|
|
25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) All other compensation includes company car allowance and medical insurance for directors, officers and their families.
(2) All other compensation additionally includes living allowance.
(3) Resigned July 18, 2005.
For further information on share incentives granted to Directors, see Share Ownership below.
The Remuneration Committee of the Board of Directors administers a bonus plan for the Companys senior executives (including Executive Directors). Such bonuses are paid at the discretion of the Remuneration Committee, in recognition of an individuals contribution to the success of the Company and the achievement of specified objectives. In 2005 the primary performance targets were a combination of objective corporate, divisional and specific individual targets. A fundamental part of the annual bonus plan is the requirement that a stated proportion of any cash bonus awarded under the bonus plan each year be deferred through the Companys Deferred Share Bonus Plan (the Plan). The Plan is designed to align the interests of senior executives with those of the shareholders by encouraging senior executives to build up and maintain shareholdings which are meaningful in the context of their remuneration. At present, participants are required to defer 50% of their bonus through the Plan. The Company currently provides one matching share (each a Matching Share) for each share acquired by a participant pursuant to the plan (each an Executive Share). Each Matching Share will be released three years after it is issued provided that performance criteria have been satisfied and the senior executive remains in employment and the corresponding Executives Shares have not been sold.
The Group operates various defined contribution plans for its employees in the U.K. and U.S. The Groups contributions to these plans are charged to the income statement in the period to which they relate, and the assets are held in separate trustee administered funds. The income statement charge related to defined contribution plans in detailed in Note 7 of the Notes to SkyePharmas Consolidated Financial Statements included in Item 17 of this Form 20-F.
The Group operates unfunded defined benefit schemes in respect of its employees in Switzerland and France.
66
The Companys Articles of Association provide that, except as otherwise provided in the Articles or unless otherwise determined by ordinary resolution of the Company, the Board of Directors (the Board) shall consist of not less than three directors. Directors of U.K. companies do not generally have fixed terms of office. At each Annual General Meeting, a number of directors equal to as close as possible (but not exceeding) one-third of the directors must retire from office by rotation, based principally on length of term of office, and are eligible for re-election. Directors may be appointed by the Company by ordinary resolution of the shareholders. In addition, the Board may appoint directors to fill vacancies or as additional directors. Any director so appointed by the Board must retire from office at the next Annual General Meeting but is then eligible for re-appointment by the shareholders at that meeting.
The Board has an Executive Committee, an Audit Committee, a Remuneration Committee and a Nominations and Governance Committee. The Executive Committee is responsible for the executive management of the Company and is chaired by the Chief Executive. The Committee comprises the Companys Executive Directors and senior management and generally meets at least monthly either in person or by conference call.
The Audit Committee is responsible for oversight of auditors, pre-approving all audit and non-audit services, reviewing and appraising the Companys financial reporting practices and procedures, the adequacy of its system of internal accounting control, reviewing the auditors report describing all critical accounting policies and practices, all alternative treatments within GAAP for material items discussed with management, other material written communications and any matters raised by its independent auditors. It also is responsible for reviewing the half-year and full-year results of the Company and its Interim and Annual Reports and Accounts prior to their submission to the full Board. The Committee reviews the cost-effectiveness, independence and objectivity of the external auditors and pre-approves all permitted non-audit expenditure incurred with the auditors. It meets formally at least three times a year. The Audit Committee is comprised of the Non-Executive Directors identified under Directors and Senior Management above and is chaired by Mr. Alan Bray.
The Remuneration Committee is responsible for approving the remuneration and other benefits, including pension contributions, bonus payments, share incentives and severance payments, of the Executive Directors and other members of senior management. The Remuneration Committee is comprised of the Non-Executive Directors identified under Directors and Senior Management.
The Nominations and Governance Committee is responsible for making recommendations to the Board on any appointment to the Board and for corporate governance matters. The Nominations and Governance Committee is comprised of the Non-Executive Directors identified under Directors and Senior Management and is chaired by Stephen Harris.
67
The following table shows the distribution of the year end number of employees, by activity and geographic location, for the last three fiscal years:
|
Year ended December 31, |
|
|||||||||||
|
|
2003 |
|
2004 |
|
2005 |
|
||||||
By category of activity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
General and Administration |
|
|
85 |
|
|
|
71 |
|
|
|
88 |
|
|
Marketing Operations |
|
|
12 |
|
|
|
5 |
|
|
|
6 |
|
|
Research and Development |
|
|
212 |
|
|
|
183 |
|
|
|
190 |
|
|
Manufacturing Operations |
|
|
157 |
|
|
|
161 |
|
|
|
161 |
|
|
|
|
|
466 |
|
|
|
420 |
|
|
|
445 |
|
|
By geographic location: |
|
|
|
|
|
|
|
|
|
|
|
|
|
U.K. |
|
|
19 |
|
|
|
16 |
|
|
|
18 |
|
|
Switzerland |
|
|
140 |
|
|
|
135 |
|
|
|
147 |
|
|
France |
|
|
141 |
|
|
|
144 |
|
|
|
139 |
|
|
Sweden |
|
|
29 |
|
|
|
1 |
|
|
|
|
|
|
U.S. and Canada |
|
|
137 |
|
|
|
124 |
|
|
|
141 |
|
|
|
|
|
466 |
|
|
|
420 |
|
|
|
445 |
|
|
Number of employees with scientific qualifications: |
|
|
|
|
|
|
|
|
|
|
|
|
|
PhDs, masters or medical degrees |
|
|
59 |
|
|
|
49 |
|
|
|
52 |
|
|
Scientists (including PhDs, masters or medical degrees) |
|
|
235 |
|
|
|
234 |
|
|
|
177 |
|
|
The Company believes that it has good relations with its employees and labor unions.
The following table sets out the interests of Directors and Senior Management in the Ordinary Shares of the Company (including the interests of their immediate families and persons connected with the Directors) as at June [], 2006.
Name |
|
|
|
Number of |
|
Percentage of |
|
||||
Dr. Argeris (Jerry) Karabelas |
|
|
206,667 |
|
|
|
0.027 |
% |
|
||
Frank Condella |
|
|
400,342 |
|
|
|
0.053 |
% |
|
||
Donald Nicholson |
|
|
955,139 |
|
|
|
0.127 |
% |
|
||
Dr. Kenneth Cunningham |
|
|
179,300 |
|
|
|
0.024 |
% |
|
||
Dr. David Ebsworth |
|
|
133,000 |
|
|
|
0.018 |
% |
|
||
Alan Bray |
|
|
170,000 |
|
|
|
0.023 |
% |
|
||
Stephen Harris |
|
|
257,299 |
|
|
|
0.034 |
% |
|
The aggregate number of Ordinary Shares held by the Directors listed in the table above at June 23, 2005 was 2,301,747, representing 0.3% of the total Ordinary Shares outstanding.
The aggregate number of Ordinary Shares underlying the Companys outstanding options and long-term incentive plan awards as of June 23, 2006 was 48,983,890.
The Company has five share option schemes (together, the Option Schemes). Grants between 1996 and 1998 were made under the 1988 Executive Share Option Scheme and the European and North American Scheme and grants from April 1999 were made under the SkyePharma PLC 1999 Share Option
68
Scheme, the European and North American 1999 Scheme and the SkyePharma Holding Inc. 1999 Stock Option Plan for SkyePharma Inc. Employees.
Executive Directors and senior executives participate in the SkyePharma PLC 1999 Share Option Scheme, the European and North American Scheme and the SkyePharma Holdings Inc. 1999 Share Option Plan as appropriate. Exercise of options granted under these plans is dependent upon total shareholder return performance measured against a peer group of companies. All options granted to Executive Directors and senior executives during 2003 were made on this basis and vest after three years on a scale between 0% and 100% depending on the Companys performance relative to that comparator group of companies. Options granted in 2001 and subsequent years will not be re-tested following vesting. If the stringent performance requirements are not met at the end of the performance period, all options will lapse.
There are two types of options under each scheme: options and Super Options. With respect to options, prior to 2001 individual participation limits under the schemes were set at four times individual remuneration. Options granted under the schemes are granted at the market price ruling at the date of grant, are exercisable after three years and up to a maximum of 10 years from date of grant. Options granted under each of the schemes may be exercised only if, over a period of three consecutive years, the shareholder return of the Company exceeds the growth in FTSE All Share Index over the same period. Prior to 2001, individual participation limits for Super Options were set at eight times remuneration. Super Options, which are also granted at the market price ruling at the date of grant, are exercisable after five years and subject to more challenging performance conditions based upon top quartile performance in the FTSE 250 Index.
SkyePharma PLC 1999 Share Option Scheme
The SkyePharma PLC 1999 Share Option Scheme (the Scheme) is divided into two parts, the first of which is approved by the Inland Revenue and the second of which is unapproved. The unapproved part is designed for the grant of options to employees, the value of which may exceed the approved limit of £30,000. Except to the extent required to obtain Inland Revenue approval, the two parts of the Scheme are similar in all material respects.
The Scheme is governed by the Rules of the Scheme and is administered by the Board. Eligibility for participation in the Scheme is limited to employees of SkyePharma, including Directors, who work for SkyePharma at least 25 hours per week and are invited to participate by the Board. No Director or employee is entitled as of right to participate in the Scheme.
Options may be granted under the Scheme within six weeks of the day on which the Company first announces its annual or interim results in any year in which the Scheme is in operation or any date on which the Directors determine that exceptional circumstances exist which justify the grant of options at that date. No consideration is payable on the grant of an option. An option may not be granted to an individual selected to participate if the total subscription price thereunder would exceed 200% of the participants remuneration in that year. Remuneration includes salary, commission and bonuses, but excludes benefits in kind. In the case of the approved part of the Scheme, participants may only be granted options up to a value of £30,000. The Board will only grant options to replace those already exercised if they are satisfied that there has been sustained improvement in the performance of the Company over not less than a two to three year period prior to such grant. Benefits under the Scheme are not pensionable.
The price per Ordinary Share at which a participant may acquire Ordinary Shares (the Option Price) on the exercise of an option will be at the discretion of the Board, but shall not be less than the market value (as defined in the Rules) of an Ordinary Share at the date of grant and shall not in any event be less than the nominal value of an Ordinary Share.
Options granted pursuant to the Scheme may not be exercised prior to the third anniversary of their grant and must be exercised before the expiry of ten years from the date of grant. Super Options may not be exercised prior to the fifth anniversary of their grant and must be exercised before the expiry of ten years from the date of grant. Options may be exercised in whole or in part in respect of any number of
69
Ordinary Shares subject to a minimum of 1,000 Ordinary Shares. An option granted under the Scheme may not be exercised unless the relevant conditions, as specified by the Directors or a committee thereof and notified to the participant no later than the date of grant, is satisfied. The performance conditions for Super Options are more challenging and in accordance with criteria recommended by the Association of British Insurers.
If a participant leaves the service of the Company by reason of injury, disability, redundancy or normal retirement, or because the company by which such participant is employed ceases to be a member of the Company, such participant will be entitled to exercise any options in accordance with the rules of the Scheme. If a participant leaves the service of the Company by reason of death, such participants personal representative will be entitled to exercise any options within 12 months following the date of such participants death. If a participant leaves the service of the Company for any reason other than the foregoing, in respect of option grants prior to 2001 such participant will be entitled to exercise any options within six months of leaving the service of the Company. For options granted during 2001 and subsequently, the options would normally lapse.
If an offeror obtains control of the Company on the occurrence of (i) a general offer to acquire the whole of the Ordinary Share capital of the Company, (ii) pursuant to an offer, an offeror becoming entitled to acquire the shares under Sections 428-430 of the Companies Act 1985 (the Act) or (iii) a compromise or arrangement being sanctioned by the Court under Section 425 of the Act, then an option holder and the offeror may agree that the options held can be exchanged for equivalent options in the offeror. Alternatively, if an offeror gains control pursuant to either a general offer or a compromise or arrangement pursuant to Section 425 of the Act, then the option holder may, in the case of a general offer, exercise his or her options within six months following the later of the date of the acquisition or the date upon which the offer becomes unconditional, or, in the case of a court order sanctioning a compromise or arrangement, within six months of that date.
Employees who receive options in excess of the £30,000 approved limit are responsible for any National Insurance contributions required in connection with the exercise of the options.
The European and North American Scheme
The European and North American Scheme is in all material aspects identical to the SkyePharma PLC 1999 Share Option Scheme, except that eligibility is restricted to employees in Europe and North America. No further grants will be made under this Scheme.
The SkyePharma Holdings Inc. 1999 Stock Option Plan for SkyePharma Inc. Employees
The SkyePharma Holdings Inc. 1999 Stock Option Plan (the Plan) is governed by the rules of the Plan and is administered by the Board of Directors of the Company acting through the Remuneration Committee. The Plan is available to all officers and key employees of SkyePharma Holdings Inc. and its subsidiaries who render services which contribute to its management, growth or financial success. Options are granted at the discretion of the Remuneration Committee. No Director or employee is entitled as of right to participate in the Plan.
Options may be granted under the Plan within six weeks of the day on which the Company first announces its annual or interim results in the year which the Plan is in operation or any date on which the Remuneration Committee determines that exceptional circumstances exist which justify the grant of options at that date.